

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : C07K 16/00, 16/42, A61K 39/00, 39/385, 39/395, G01N 33/577, 33/68, A61P 37/08		A1	(11) International Publication Number: WO 00/50461
			(43) International Publication Date: 31 August 2000 (31.08.00)
(21) International Application Number: PCT/EP00/01456		Road, Cambridge CB1 9PT (GB). TURNELL, William, Gordon [GB/GB]; Peptide Therapeutics Limited, Peterhouse Technology Park, 100 Fulbourn Road, Cambridge CB1 9PT (GB). VAN MECHELEN, Marcelle, Paulette [GB/GB]; SmithKline Beecham Biologicals S.A., rue de l'Institut 89, B-1330 Rixensart (GB). VINALS Y DE BASSOLS, Carlota [BE/BE]; Smithkline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE).  (74) Agent: DALTON, Marcus, Jonathan, William; SmithKline Beecham, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).  (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 22 February 2000 (22.02.00)			
(30) Priority Data:			
9904408.3 25 February 1999 (25.02.99) GB 9917144.9 21 July 1999 (21.07.99) GB 9918598.5 7 August 1999 (07.08.99) GB 9918599.3 7 August 1999 (07.08.99) GB 9918601.7 7 August 1999 (07.08.99) GB 9918604.1 7 August 1999 (07.08.99) GB 9918606.6 7 August 1999 (07.08.99) GB 9925618.2 29 October 1999 (29.10.99) GB			
(71) Applicants (for all designated States except US): SMITHKLINE BEECHAM BIOLOGICALS S.A. [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE). PEPTIDE THERAPEUTICS LIMITED [GB/GB]; Peterhouse Technology Park, 100, Fulbourn Road, Cambridge CB1 9PT (GB).			
(72) Inventors; and		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(75) Inventors/Applicants (for US only): FRIEDE, Martin [GB/GB]; Corporate Intellectual Property, SmithKline Beecham, 2 New Horizons Court, Brentford, Middlesex TW8 9EP (GB). MASON, Sean [GB/GB]; Peptide Therapeutics Limited, Peterhouse Technology Park, 100 Fulbourn			
(54) Title: EPITOPES OR MIMOTOPES DERIVED FROM THE C-EPSILON-3 OR C-EPSILON-4 DOMAINS OF IGE, ANTAGONISTS THEREOF, AND THEIR THERAPEUTIC USES			
(57) Abstract			
<p>The present invention relates to the provision of novel medicaments for the treatment, prevention or amelioration of allergic disease. In particular, the novel medicaments are epitopes or mimotopes derived from the Cε3 or Cε4 domains of IgE. These novel regions may be the target for both passive and active immunoprophylaxis or immunotherapy. The invention further relates to methods for production of the medicaments, pharmaceutical compositions containing them and their use in medicine. Also forming an aspect of the present invention are ligands, especially monoclonal antibodies, which are capable of binding the IgE regions of the present invention, and their use in medicine as passive immunotherapy or immunoprophylaxis.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## EPITOPES OR MIMOTOPES DERIVED FROM THE C-EPSILON-3 OR C-EPSILON-4 DOMAINS OF IGE, ANTAGONISTS THEREOF, AND THEIR THERAPEUTIC USES

The present invention relates to the provision of novel medicaments for the treatment, prevention or amelioration of allergic disease. In particular, the novel  
5 medicaments are epitopes or mimotopes derived from the Cε3 or Cε4 domains of IgE. These novel regions may be the target for both passive and active immunoprophylaxis or immunotherapy. The invention further relates to methods for production of the medicaments, pharmaceutical compositions containing them and their use in medicine. Also forming an aspect of the present invention are ligands, especially  
10 monoclonal antibodies, which are capable of binding the IgE regions of the present invention, and their use in medicine as passive immunotherapy or immunoprophylaxis.

In an allergic response, the symptoms commonly associated with allergy are brought about by the release of allergic mediators, such as histamine, from immune  
15 cells into the surrounding tissues and vascular structures. Histamine is normally stored in mast cells and basophils, until such time as the release is triggered by interaction with allergen specific IgE. The role of IgE in the mediation of allergic responses, such as asthma, food allergies, atopic dermatitis, type-I hypersensitivity and allergic rhinitis, is well known. On encountering an antigen, such as pollen or dust mite  
20 allergens, B-cells commence the synthesis of allergen specific IgE. The allergen specific IgE then binds to the FcεRI receptor (the high affinity IgE receptor) on basophils and mast cells. Any subsequent encounter with allergen leads to the triggering of histamine release from the mast cells or basophils, by cross-linking of neighbouring IgE/ FcεRI complexes (Sutton and Gould, Nature, 1993, 366: 421-428;  
25 EP 0 477 231 B1).

IgE, like all immunoglobulins, comprises two heavy and two light chains. The ε heavy chain consists of five domains: one variable domain (VH) and four constant domains (Cε1 to Cε4). The molecular weight of IgE is about 190,000 Da, the heavy chain being approximately 550 amino acids in length. The structure of IgE is  
30 discussed in Padlan and Davis (Mol. Immunol., 23, 1063-75, 1986) and Helm et al., (2IgE model structure deposited 2/10/90 with PDB (Protein Data Bank, Research Collaboratory for Structural Bioinformatics; <http://pdb-browsers.ebi.ac.uk>)). Each of

the IgE domains consists of a squashed barrel of seven anti-parallel strands of extended ( $\beta$ -) polypeptide segments, labelled a to f, grouped into two  $\beta$ -sheets. Four  $\beta$ -strands (a, b, d & e) form one sheet that is stacked against the second sheet of three strands (c, f & g) (see FIG. 8). The shape of each  $\beta$ -sheet is maintained by lateral  
5 packing of amino acid residue side-chains from neighbouring anti-parallel strands within each sheet (and is further stabilised by main-chain hydrogen-bonding between these strands). Loops of residues, forming non-extended (non- $\beta$ -) conformations, connect the anti-parallel  $\beta$ -strands, either within a sheet or between the opposing sheets. The connection from strand a to strand b is labelled as the A-B loop, and so  
10 on. The A-B and d-e loops belong topologically to the four-stranded sheet, and loop f-g to the three-stranded sheet. The interface between the pair of opposing sheets provides the hydrophobic interior of the globular domain. This water-inaccessible, mainly hydrophobic core results from the close packing of residue side-chains that face each other from opposing  $\beta$ -sheets.

15 In the past, a number of passive or active immunotherapeutic approaches designed to interfere with IgE-mediated histamine release mechanism have been investigated. These approaches include interfering with IgE or allergen/IgE complexes binding to the Fc $\epsilon$ RI or Fc $\epsilon$ RII (the low affinity IgE receptor) receptors, with either passively administered antibodies, or with passive administration of IgE derived  
20 peptides to competitively bind to the receptors. In addition, some authors have described the use of specific peptides derived from IgE in active immunisation to stimulate histamine release inhibiting immune responses.

In the course of their investigations, previous workers in this field have encountered a number of considerations, and problems, which have to be taken into  
25 account when designing new anti-allergy therapies. One of the most dangerous problems revolves around the involvement of IgE cross-linking in the histamine release signal. It is most often the case that the generation of anti-IgE antibodies during active vaccination, are capable of triggering histamine release *per se*, by the cross-linking of neighbouring IgE-receptor complexes in the absence of allergen. This  
30 phenomenon is termed anaphylactogenicity. Indeed many commercially available anti-IgE monoclonal antibodies which are normally used for IgE detection assays, are

anaphylactogenic, and consequently useless and potentially dangerous if administered to a patient.

Whether or not an antibody is anaphylactogenic, depends on the location of the target epitope on the IgE molecule. However, based on the present state of knowledge in this area, and despite enormous scientific interest and endeavour, there is little or no predictability of what characteristics any antibody or epitope may have and whether or not it might have a positive or negative clinical effect on a patient.

Therefore, in order to be safe and effective, the passively administered, or vaccine induced, antibodies must bind in a region of IgE which is capable of interfering with the histamine triggering pathway, without being anaphylactic *per se*. The present invention achieves all of these aims and provides medicaments which are capable of raising non-anaphylactic antibodies which inhibit histamine release. These medicaments may form the basis of an active vaccine or be used to raise appropriate antibodies for passive immunotherapy, or may be passively administered themselves for a therapeutic effect.

Much work has been carried out by those skilled in the art to identify specific anti-IgE antibodies which do have some beneficial effects against IgE-mediated allergic reaction (WO 90/15878, WO 89/04834, WO 93/05810). Attempts have also been made to identify epitopes recognised by these useful antibodies, to create peptide mimotopes of such epitopes and to use those as immunogens to produce anti-IgE antibodies.

WO 97/31948 describes an example of this type of work, and further describes IgE peptides from the Cε3 and Cε4 domains conjugated to carrier molecules for active vaccination purposes. These immunogens may be used in vaccination studies and are said to be capable of generating antibodies which subsequently inhibit histamine release *in vivo*. In this work, a monoclonal antibody (BSW17) was described which was said to be capable of binding to IgE peptides contained within the Cε3 domain which are useful for active vaccination purposes.

EP 0 477 231 B1 describes immunogens derived from the Cε4 domain of IgE (residues 497-506, also known as the Stanworth decapeptide), conjugated to Keyhole Limpet Haemocyanin (KLH) used in active vaccination immunoprophylaxis. WO 96/14333 is a continuation of the work described in EP 0 477 231 B1.

Other approaches are based on the identification of peptides derived from Cε3 or Cε4, which themselves compete for IgE binding to the high or low affinity receptors on basophils or mast cells (WO 93/04173, WO 98/24808, EP 0 303 625 B1, EP 0 341 290).

5 The present invention is the identification of novel sequences of IgE which are used in active or passive immunoprophylaxis or therapy. These sequences have not previously been associated with anti-allergy treatments. The present invention provides peptides, *per se*, that incorporate specific isolated epitopes from continuous portions of IgE which have been identified as being surface exposed, and further  
10 provides mimotopes of these newly identified epitopes. These peptides or mimotopes may be used alone in the treatment of allergy, or may be used vaccines to induce auto anti-IgE antibodies during active immunoprophylaxis or immunotherapy of allergy to limit, reduce, or eliminate allergic symptoms in vaccinated subjects.

Surprisingly, the anti-IgE antibodies induced by the peptides of the present  
15 invention are non-anaphylactogenic and are capable of blocking IgE-mediated histamine release from mast cells and basophils.

The regions of human IgE which are peptides of the present invention, and which may serve to provide the basis for peptide modification are:

20 **Table 1**

<i>Peptide</i>	<i>Sequence</i>	<i>Location sequence and IgE Domain</i>	<i>SEQ ID NO.</i>
P5	RASGKPVNHSTRKEEKQRNGTL	Cε3	1
P6	GTRDWIEGE	Cε3	2
P7	PHLPRALMRSTTKTSGPRA	Cε3/Cε4	3
P8	PEWPGSRDKRT	Cε4 (Pro451-Thr461)	4
P9	EQKDE	Cε4	5
P200	LSRPSPFDLFIRKSPTITC	Cε3	6
P210	WLHNEVQLPDARHSTTQPRKT	Cε4	7
1-90N	LFIRKS	Cε3	81
2-90N	PSKGTVN	Cε3	82
3-90N	LHNEVQLPDARHSTTQPRKTKGS	Cε4	83
4-90N	SVNPGK	Cε4	84

Peptides that incorporate these epitopes form a preferred aspect of the present invention. Mimotopes which have the same characteristics as these epitopes, and



immunogens comprising such mimotopes which generate an immune response which cross-react with the IgE epitope in the context of the IgE molecule, also form part of the present invention.

The present invention, therefore, includes isolated peptides encompassing these IgE epitopes themselves, and any mimotope thereof. The meaning of mimotope is defined as an entity which is sufficiently similar to the native IgE epitope so as to be capable of being recognised by antibodies which recognise the native IgE epitope; (Gheysen, H.M., et al., 1986, Synthetic peptides as antigens. Wiley, Chichester, Ciba foundation symposium 119, p130-149; Gheysen, H.M., 1986, Molecular Immunology, 23,7, 709-715); or are capable of raising antibodies, when coupled to a suitable carrier, which antibodies cross-react with the native IgE epitope.

The mimotopes of the present invention may be peptidic or non-peptidic. A peptidic mimotope of the surface exposed IgE epitopes identified above, may also be of exactly the same sequence as the native epitope. Such a molecule is described as a mimotope of the epitope, because although the two molecules share the same sequence, the mimotope will not be presented in the context of the whole IgE domain structure, and as such the mimotope may take a slightly different conformation to that of the native IgE epitope. It will also be clear to the man skilled in the art that the above identified linear sequences (P1 to P7), when in the tertiary structure of IgE, lie adjacent to other regions that may be distant in the primary sequence of IgE. As such, for example, a mimotope of P1 may be continuous or discontinuous, in that it comprises or mimics segments of P1 and segments made up of these distant amino acid residues.

The mimotopes of the present invention mimic the surface exposed regions of the IgE structure, however, within those regions the dominant aspect is thought by the present inventors to be those regions within the surface exposed area which correlate to a loop structure. The structure of the domains of IgE are described in "Introduction to protein Structure" (page 304, 2<sup>nd</sup> Edition, Branden and Tooze, Garland Publishing, New York, ISBN 0 8153 2305-0) and take the form a  $\beta$ -barrel made up of two opposing anti-parallel  $\beta$ -sheets (see FIG. 8). The mimotopes may comprise, therefore, a loop with N or C terminal extensions which may be the natural amino acid residues from neighbouring sheets. As examples of this, P100 contains the A-B loop of C $\epsilon$ 3,

P8 contains the A-B loop of C $\epsilon$ 4, P5 contains the C-D loop of C $\epsilon$ 3 and P110 contains the C-D loop of C $\epsilon$ 4. Accordingly, mimotopes of these loops form an aspect of the present invention. Particularly preferred loops are the C-D loops of C $\epsilon$ 3 or C $\epsilon$ 4, and the A-B loop of C $\epsilon$ 4.

5 Peptide mimotopes of the above-identified IgE epitopes may be designed for a particular purpose by addition, deletion or substitution of elected amino acids. Thus, the peptides of the present invention may be modified for the purposes of ease of conjugation to a protein carrier. For example, it may be desirable for some chemical conjugation methods to include a terminal cysteine to the IgE epitope. In addition it  
10 may be desirable for peptides conjugated to a protein carrier to include a hydrophobic terminus distal from the conjugated terminus of the peptide, such that the free unconjugated end of the peptide remains associated with the surface of the carrier protein. This reduces the conformational degrees of freedom of the peptide, and thus increases the probability that the peptide is presented in a conformation which most  
15 closely resembles that of the IgE peptide as found in the context of the whole IgE molecule. For example, the peptides may be altered to have an N-terminal cysteine and a C-terminal hydrophobic amidated tail. Alternatively, the addition or substitution of a D-stereoisomer form of one or more of the amino acids may be performed to create a beneficial derivative, for example to enhance stability of the peptide. Those  
20 skilled in the art will realise that such modified peptides, or mimotopes, could be a wholly or partly non-peptide mimotope wherein the constituent residues are not necessarily confined to the 20 naturally occurring amino acids. In addition, these may be cyclised by techniques known in the art to constrain the peptide into a conformation that closely resembles its shape when the peptide sequence is in the  
25 context of the whole IgE molecule. A preferred method of cyclising a peptide comprises the addition of a pair of cysteine residues to allow the formation of a disulphide bridge.

Further, those skilled in the art will realise that mimotopes or immunogens of  
30 the present invention may be larger than the above-identified epitopes, and as such may comprise the sequences disclosed herein. Accordingly, the mimotopes of the present invention may consist of addition of N and/or C terminal extensions of a number of other natural residues at one or both ends. The peptide mimotopes may also

be retro sequences of the natural IgE sequences, in that the sequence orientation is reversed; or alternatively the sequences may be entirely or at least in part comprised of D-stereo isomer amino acids (inverso sequences). Also, the peptide sequences may be retro-inverso in character, in that the sequence orientation is reversed and the amino acids are of the D-stereoisomer form. Such retro or retro-inverso peptides have the advantage of being non-self, and as such may overcome problems of self-tolerance in the immune system (for example P14c).

Alternatively, peptide mimotopes may be identified using antibodies which are capable themselves of binding to the IgE epitopes of the present invention using techniques such as phage display technology (EP 0 552 267 B1). This technique, generates a large number of peptide sequences which mimic the structure of the native peptides and are, therefore, capable of binding to anti-native peptide antibodies, but may not necessarily themselves share significant sequence homology to the native IgE peptide. This approach may have significant advantages by allowing the possibility of identifying a peptide with enhanced immunogenic properties (such as higher affinity binding characteristics to the IgE receptors or anti-IgE antibodies, or being capable of inducing polyclonal immune response which binds to IgE with higher affinity), or may overcome any potential self-antigen tolerance problems which may be associated with the use of the native peptide sequence. Additionally this technique allows the identification of a recognition pattern for each native-peptide in terms of its shared chemical properties amongst recognised mimotope sequences.

Examples of such mimotopes are:

Table 2

Peptide	Sequence	Description	SEQ ID NO.
P11	CRASGKPVNHSTRKEEKQRNGLL	P5 mimotope	8
P11a	(Ac) GKPVNHSTGGC	P5 mimotope	9
P11b	(Ac) GKPVNHSTRKEEKQRNGC	P5 mimotope	10
P11c	CGKPVNHSTRKEEKQRNGLL (NH <sub>2</sub> )	P5 mimotope	11
P11d	(Ac) RASGKPVNHSTGGC	P5 mimotope	12
P12	CGTRDWIEGLL	P6 mimotope	13
P12a	CGTRDWIEGETL (NH <sub>2</sub> )	P6 mimotope	14
P12b	(Ac) GTRDWIEGETGC	P6 mimotope	15
P13	CHPHLPRALMLL	P7 mimotope	16
P13a	CGTHPHLPRALM (NH <sub>2</sub> )	P7 mimotope	17
P13b	(Ac) THPHLPRALMRSC	P7 mimotope	18
P13c	(Ac) GPHLPRALMRSSSC	P7 mimotope	19
P14	APEWPGSRDKRTC	P8 mimotope	20
P14a	(Ac) APEWPGSRDKRTLGGC	P8 mimotope	21
P14b	CGGATPEWPGSRDKRTL (NH <sub>2</sub> )	P8 mimotope	22
P14c	CTRKDRSGPWEPA (NH <sub>2</sub> )	P8 retro	23
P14d* (cyclic)	(Ac) APCWPGSRDCRTLAG	P8 mimotope	24
P14d (cyclic)	(Ac) ACPEWPGSRDRCTLAG	P8 mimotope	25
C-1C14	CATPEWPGSRDKRTLGC	P8 mimotope	26
C-1C13	CATPEWPGSRDKRTCG	P8 mimotope	27
C3C12	TPCWPGSRDKRCG	P8 mimotope	28
P9a	CGAEWEQKDEL (NH <sub>2</sub> )	P9 mimotope	29
P9b	(Ac) AEWEQKDEFIC	P9 mimotope	30
P9b*	(Ac) GEQKDEFIC	P9 mimotope	31
P9a*	CAEGEQKDEL (NH <sub>2</sub> )	P9 mimotope	32
Carl1	CPEWPGCRDKRTG	P8 mimotope	85
Carl2	TPEWPGCRDKRCG	P8 mimotope	86

Alternatively, peptide mimotopes may be generated with the objective of increasing the immunogenicity of the peptide by increasing its affinity to the anti-IgE peptide polyclonal antibody, the effect of which may be measured by techniques known in the art such as (Biocore experiments). In order to achieve this the peptide sequence may be electively changed following the general rules:

- \* To maintain the structural constraints, prolines and glycines should not be replaced

- \* Other positions can be substituted by an amino acid that has similar physicochemical properties.

As such, each amino acid residue can be replaced by the amino acid that most closely resembles that amino acid. For example, A may be substituted by V, L or I, as

5 described in the following table.

Original residue	Exemplary substitutions	Preferred substitution
A	V, L, I	V
R	K, Q, N	K
N	Q, H, K, R	Q
D	E	E
C	S	S
Q	N	N
E	D	D
G	A	A
H	N, Q, K, R	N
I	L, V, M, A, F	L
L	I, V, M, A, F	I
K	R, Q, N	R
M	L, F, I	L
F	L, V, I, A, Y, W	W
P	A	A
S	T	T
T	S	S
W	Y, F	Y
Y	W, F, T, S	F
V	I, L, M, F, A	L

Particularly preferred IgE peptides are P8 and variants thereof (such as P14 or P14a). These peptides, when coupled to a carrier are potent in inducing anti-IgE immune responses, which responses are capable of inhibiting histamine release from human basophils. Variants, or mimotopes, of P8 are described primarily as any peptide based immunogen which is capable of inducing an immune response, which response is capable of recognising P8. Without being limiting to the scope of the present invention, some variants of P8 may be described by a general formula in which certain amino acids may be replaced by their closest counterparts. Using this technique, P8 peptide mimotopes may be described by the general formula:

P, X<sub>1</sub>, X<sub>2</sub>, P, X<sub>3</sub>, X<sub>4</sub>, X<sub>5</sub>, X<sub>6</sub>, X<sub>5</sub>, X<sub>5</sub>

or,

P, X<sub>1</sub>, X<sub>2</sub>, P, G, X<sub>4</sub>, R, D, X<sub>5</sub>, X<sub>6</sub>

wherein; X<sub>1</sub> is an amino acid selected from E, D, N, or Q; X<sub>2</sub> is an amino acid selected from W, Y, or F; X<sub>3</sub> is an amino acid selected from G or A, X<sub>4</sub> is an amino acid selected from S, T or M; X<sub>5</sub> is an amino acid selected from R or K; and X<sub>6</sub> is an amino acid selected from D or E.

P8 mimotopes may also be identified using antibodies which are capable themselves of binding to P8, using techniques such as phage display technology (EP 0 552 267 B1). Monoclonal antibodies such as P14/23, P14/31 and P14/33 are particularly suitable in this regard.

The present invention, therefore, provides novel epitopes, and mimotopes thereof, and their use in the manufacture of pharmaceutical compositions for the prophylaxis or therapy of allergies. Immunogens comprising at least one of the epitopes or mimotopes of the present invention and carrier molecules are also provided for use in vaccines for the immunoprophylaxis or therapy of allergies.

Accordingly, the epitopes, mimotopes, or immunogens of the present invention are provided for use in medicine, and in the medical treatment or prophylaxis of allergic disease. Preferred immunogens and vaccines of the present invention comprise the IgE epitope P8, or mimotopes thereof, including P14.

The present inventors have shown that different methods by which the epitope or mimotope is presented has significant effects upon binding to monoclonal antibodies and to the immune response after vaccination. For example, when using cyclised peptides, altering the length and phase of the loop may have significant effects on the binding activity of the cyclised mimotopes to the P14 monoclonal antibodies (P14/23, P14/31 or P14/33). As such the present inventors have developed a novel system which selects the sites of cyclisation, thereby increasing the probability that the cyclised peptides are held in the correct loop structure, which comprises the correct amino acid residues. In this way, the peptide is likely to be constrained in a conformation that most closely resembles that which the peptides would normally adopt if they were in the context of the whole IgE domain. Hence, without limiting the present invention the cyclised mimotopes which follow these new rules form one preferred aspect of the present invention.

Putative mimotope sequences that are not consistent with these rules may still raise useful antisera (for example P14 and P11), as such the following examples are only a sub-set of the types of mimotopes of the present invention.

5 Examples of preferred peptides that follow these newly defined structural rules are:

**Table 3**

<i>Peptide sequence</i>	<i>Mimotope of</i>	<i>SEQ ID NO.</i>
CSRSPFDLFIRKSPTITC	A-B loop of Cε3	33
CSRSPFDLFIRKSPTC	A-B loop of Cε3	35
CSPFDLFIRKSPTITC	A-B loop of Cε3	41
CSPFDLFIRKSPC	A-B loop of Cε3	43
CTWSRASGKPVNHSTC	C-D loop of Cε3	58
CTWSRASGKPVNHC	C-D loop of Cε3	60
CSRASGKPVNHSTC	C-D loop of Cε3	66
CSRASGKPVNHC	C-D loop of Cε3	68
CYAFATPEWPGSRDKRTLAC	A-B loop of Cε4	45
CYAFATPEWPGSRDKRTC	A-B loop of Cε4	47
CFATPEWPGSRDKRTLAC	A-B loop of Cε4	53
CFATPEWPGSRDKRTC	A-B loop of Cε4	55
CQWLHNEVQLPDARHC	C-D loop of Cε4	70
CQWLHNEVQLPDAC	C-D loop of Cε4	72
CLHNEVQLPDARHC	C-D loop of Cε4	78
CLHNEVQLPDAC	C-D loop of Cε4	80

It is envisaged that the mimotopes of the present invention will be of a small size, such that they mimic a region selected from the whole IgE domain in which the native epitope is found. Peptidic mimotopes, therefore, should be less than 100 amino acids in length, preferably shorter than 75 amino acids, more preferably less than 50 amino acids, and most preferable within the range of 4 to 25 amino acids long. Specific examples of preferred peptide mimotopes are P14 and P11, which are respectively 13 and 23 amino acids long. Non-peptidic mimotopes are envisaged to be of a similar size, in terms of molecular volume, to their peptidic counterparts.

It will be apparent to the man skilled in the art which techniques may be used to confirm the status of a specific construct as a mimotope which falls within the scope of the present invention. Such techniques include, but are not restricted to, the following. The putative mimotope can be assayed to ascertain the immunogenicity of the construct, in that antisera raised by the putative mimotope cross-react with the

native IgE molecule, and are also functional in blocking allergic mediator release from allergic effector cells. The specificity of these responses can be confirmed by competition experiments by blocking the activity of the antiserum with the mimotope itself or the native IgE, and/or specific monoclonal antibodies that are known to bind the epitope within IgE. Specific examples of such monoclonal antibodies for use in the competition assays include P14/23, P14/31 or P14/33, which would confirm the status of the putative mimotope as a mimotope of P8.

In one embodiment of the present invention at least one IgE epitope or mimotope are linked to carrier molecules to form immunogens for vaccination protocols, preferably wherein the carrier molecules are not related to the native IgE molecule. The mimotopes may be linked via chemical covalent conjugation or by expression of genetically engineered fusion partners, optionally *via* a linker sequence. As one embodiment, the peptides of the present invention are expressed in a fusion molecule with the fusion partner, wherein the peptide sequence is found within the primary sequence of the fusion partner.


The covalent coupling of the peptide to the immunogenic carrier can be carried out in a manner well known in the art. Thus, for example, for direct covalent coupling it is possible to utilise a carbodiimide, glutaraldehyde or (N-[ $\gamma$ -maleimidobutyryloxy] succinimide ester, utilising common commercially available heterobifunctional linkers such as CDAP and SPDP (using manufacturers instructions). After the coupling reaction, the immunogen can easily be isolated and purified by means of a dialysis method, a gel filtration method, a fractionation method etc.

In a preferred embodiment the present inventors have found that peptides, particularly cyclised peptides may be conjugated to the carrier by preparing Acylhydrazine peptide derivatives.

The peptides/protein carrier constructs can be produced as follows.

Acylhydrazine peptide derivatives can be prepared on the solid phase as shown in the following scheme 1 Solid Phase Peptide Synthesis:



Scheme 1



These peptide derivatives can be readily prepared using the well-known

5 'Fmoc' procedure, utilising either polyamide or polyethyleneglycol-polystyrene (PEG-PS) supports in a fully automated apparatus, through techniques well known in the art [techniques and procedures for solid phase synthesis are described in 'Solid


Phase Peptide Synthesis: A Practical Approach' by E. Atherton and R.C. Sheppard, published by IRL at Oxford University Press (1989)]. Acid mediated cleavage afforded the linear, deprotected, modified peptide. This could be readily oxidised and purified to yield the disulphide-bridged modified epitope using methodology outlined in 'Methods in Molecular Biology, Vol. 35: Peptide Synthesis Protocols (ed. M.W. Pennington and B.M. Dunn), chapter 7, pp91-171 by D. Andreau et al.

The peptides thus synthesised can then be conjugated to protein carriers using the following technique:

Introduction of the aryl aldehyde functionality utilised the succinimido active ester (BAL-OSu) prepared as shown in scheme 2 (see WO 98/17628 for further details). Substitution of the amino functions of a carrier eg BSA (bovine serum albumin) to ~50% routinely give soluble modified protein. Greater substitution of the BSA leads to insoluble constructs. BSA and BAL-OSu were mixed in equimolar concentration in DMSO/buffer (see scheme) for 2 hrs. This experimentally derived protocol gives ~50% substitution of BSA as judged by the Fluorescamine test for free amino groups in the following Scheme 2/3 – Modified Carrier Preparation:

Scheme 2Scheme 3

Simple combination of modified peptide and derivatised carrier affords peptide carrier constructs readily isolated by dialysis – Scheme 4 – Peptide/carrier conjugate:

Scheme 4

The types of carriers used in the immunogens of the present invention will be readily known to the man skilled in the art. The function of the carrier is to provide cytokine help in order to help induce an immune response against the IgE peptide. A non-exhaustive list of carriers which may be used in the present invention include: Keyhole limpet Haemocyanin (KLH), serum albumins such as bovine serum albumin (BSA), inactivated bacterial toxins such as tetanus or diphtheria toxins (TT and DT), or recombinant fragments thereof (for example, Domain 1 of Fragment C of TT, or the translocation domain of DT), or the purified protein derivative of tuberculin (PPD). Alternatively the mimotopes or epitopes may be directly conjugated to liposome carriers, which may additionally comprise immunogens capable of providing T-cell help. Preferably the ratio of mimotopes to carrier is in the order of 1:1 to 20:1, and preferably each carrier should carry between 3-15 peptides.

In an embodiment of the invention a preferred carrier is Protein D from *Haemophilus influenzae* (EP 0 594 610 B1). Protein D is an IgD-binding protein from *Haemophilus influenzae* and has been patented by Forsgren (WO 91/18926, granted

EP 0 594 610 B1). In some circumstances, for example in recombinant immunogen expression systems it may be desirable to use fragments of protein D, for example Protein D 1/3<sup>rd</sup> (comprising the N-terminal 100-110 amino acids of protein D (GB 9717953.5)).

5           Another preferred method of presenting the IgE peptides of the present invention is in the context of a recombinant fusion molecule. For example, EP 0 421 635 B describes the use of chimaeric hepadnavirus core antigen particles to present foreign peptide sequences in a virus-like particle. As such, immunogens of the present invention may comprise IgE peptides presented in chimaeric particles consisting of  
10   hepatitis B core antigen. Additionally, the recombinant fusion proteins may comprise the mimotopes of the present invention and a carrier protein, such as NS1 of the influenza virus. For any recombinantly expressed protein which forms part of the present invention, the nucleic acid which encodes said immunogen also forms an aspect of the present invention.

15           Peptides used in the present invention can be readily synthesised by solid phase procedures well known in the art. Suitable syntheses may be performed by utilising "T-boc" or "F-moc" procedures. Cyclic peptides can be synthesised by the solid phase procedure employing the well-known "F-moc" procedure and polyamide resin in the fully automated apparatus. Alternatively, those skilled in the art will know  
20   the necessary laboratory procedures to perform the process manually. Techniques and procedures for solid phase synthesis are described in 'Solid Phase Peptide Synthesis: A Practical Approach' by E. Atherton and R.C. Sheppard, published by IRL at Oxford University Press (1989). Alternatively, the peptides may be produced by recombinant methods, including expressing nucleic acid molecules encoding the mimotopes in a  
25   bacterial or mammalian cell line, followed by purification of the expressed mimotope. Techniques for recombinant expression of peptides and proteins are known in the art, and are described in Maniatis, T., Fritsch, E.F. and Sambrook et al., *Molecular cloning, a laboratory manual*, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989).

30           The immunogens of the present invention may comprise the peptides as previously described, including mimotopes or analogues thereof, or may be immunologically cross-reactive derivatives or fragments thereof. Also forming part of

the present invention are portions of nucleic acid which encode the immunogens of the present invention or peptides, mimotopes or derivatives thereof.

The present invention, therefore, provides the use of novel epitopes or mimotopes (as defined above) in the manufacture of pharmaceutical compositions for the prophylaxis or therapy of allergies. Immunogens comprising the mimotopes or peptides of the present invention, and carrier molecules are also provided for use in vaccines for the immunoprophylaxis or therapy of allergies. Accordingly, the mimotopes, peptides or immunogens of the present invention are provided for use in medicine, and in the medical treatment or prophylaxis of allergic disease.

Vaccines of the present invention, may advantageously also include an adjuvant. Suitable adjuvants for vaccines of the present invention comprise those adjuvants that are capable of enhancing the antibody responses against the IgE peptide immunogen. Adjuvants are well known in the art (Vaccine Design – The Subunit and Adjuvant Approach, 1995, Pharmaceutical Biotechnology, Volume 6, Eds. Powell, M.F., and Newman, M.J., Plenum Press, New York and London, ISBN 0-306-44867-X). Preferred adjuvants for use with immunogens of the present invention include aluminium or calcium salts (hydroxide or phosphate).

The vaccines of the present invention will be generally administered for both priming and boosting doses. It is expected that the boosting doses will be adequately spaced, or preferably given yearly or at such times where the levels of circulating antibody fall below a desired level. Boosting doses may consist of the peptide in the absence of the original carrier molecule. Such booster constructs may comprise an alternative carrier or may be in the absence of any carrier.

In a further aspect of the present invention there is provided an immunogen or vaccine as herein described for use in medicine.

The vaccine preparation of the present invention may be used to protect or treat a mammal susceptible to, or suffering from allergies, by means of administering said vaccine via systemic or mucosal route. These administrations may include injection *via* the intramuscular, intraperitoneal, intradermal or subcutaneous routes; or *via* mucosal administration to the oral/alimentary, respiratory, genitourinary tracts. A preferred route of administration is *via* the transdermal route, for example by skin patches. Accordingly, there is provided a method for the treatment of allergy,

comprising the administration of a peptide, immunogen, or ligand of the present invention to a patient who is suffering from or is susceptible to allergy.

The amount of protein in each vaccine dose is selected as an amount which induces an immunoprotective response without significant adverse side effects in  
5 typical vaccinees. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Generally, it is expected that each dose will comprise 1-1000  $\mu\text{g}$  of protein, preferably 1-500  $\mu\text{g}$ , more preferably 1-100  $\mu\text{g}$ , of which 1 to 50  $\mu\text{g}$  is the most preferable range. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of appropriate  
10 immune responses in subjects. Following an initial vaccination, subjects may receive one or several booster immunisations adequately spaced.

In a related aspect of the present invention are ligands capable of binding to the peptides of the present invention. Example of such ligands are antibodies (or Fab fragments). Also provided are the use of the ligands in medicine, and in the  
15 manufacture of medicaments for the treatment of allergies. The term "antibody" herein is used to refer to a molecule having a useful antigen binding specificity. Those skilled in the art will readily appreciate that this term may also cover polypeptides which are fragments of or derivatives of antibodies yet which can show the same or a closely similar functionality. Such antibody fragments or derivatives are intended to  
20 be encompassed by the term antibody as used herein.

Particularly preferred ligands are monoclonal antibodies. For example, P14/23, P14/31 or P14/33 are monoclonal antibodies which recognise P8 (which were raised by vaccination with a P14 immunogen). The hybridomas of these antibodies were deposited as Budapest Treaty patent deposit at ECACC (European Collection of Cell  
25 Cultures, Vaccine Research and Production Laboratory, Public Health Laboratory Service, Centre for Applied Microbiology Research, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK) on 26 January 2000 under Accession No.s 00012610, 00012611, 00012612 respectively. Also forming an important aspect of the present invention is the use of these monoclonal antibodies in the identification of novel  
30 mimotopes of IgE, for subsequent use in allergy therapy, and the use of the antibodies in the manufacture of a medicament for the treatment or prophylaxis of allergy. All of these monoclonal antibodies function *in vitro* in inhibiting histamine release from

human basophils, and also P14/23 and P14/31 have been shown to inhibit passive cutaneous anaphylaxis *in vivo*.

Therefore, mimotopes of IgE Cε4 that are capable of binding to P14/23, P14/31 or P14/33, and immunogens comprising these mimotopes, form an important aspect of the present invention. Vaccines comprising mimotopes that are capable of binding to P14/23, P14/31 or P14/33 are useful in the treatment of allergy.

Additionally, antibodies induced in one animal by vaccination with the peptides or immunogens of the present invention, may be purified and passively administered to another animal for the prophylaxis or therapy of allergy. The peptides of the present invention may also be used for the generation of monoclonal antibody hybridomas (using known techniques *e.g.* Köhler and Milstein, Nature, 1975, 256, p495), humanised monoclonal antibodies or CDR grafted monoclonals, by techniques known in the art. Such antibodies may be used in passive immunoprophylaxis or immunotherapy, or be used in the identification of IgE peptide mimotopes.

As the ligands of the present invention may be used for the prophylaxis or treatment of allergy, there is provided pharmaceutical compositions comprising the ligands of the present invention. Preferred pharmaceutical compositions for the treatment or prophylaxis of allergy comprise the monoclonal antibodies P14/23, P14/31 or P14/33.

Aspects of the present invention may also be used in diagnostic assays. For example, panels of ligands which recognise the different peptides of the present invention may be used in assaying titres of anti-IgE present in serum taken from patients. Moreover, the peptides may themselves be used to type the circulating anti-IgE. It may in some circumstances be appropriate to assay circulating anti-IgE levels, for example in atopic patients, and as such the peptides and poly/mono-clonal antibodies of the present invention may be used in the diagnosis of atopy. In addition, the peptides may be used to affinity remove circulating anti-IgE from the blood of patients before re-infusion of the blood back into the patient.

Also forming part of the present invention is a method of identifying peptide immunogens for the immunoprophylaxis or therapy of allergy comprising using a computer model of the structure of IgE, and identifying those peptides of the IgE which are surface exposed. These regions may then be formulated into immunogens



and used in medicine. Accordingly, the use of P14/23, P14/31 or P14/33 in the identification of peptides for use in allergy immunoprophylaxis or therapy forms part of the present invention.

Vaccine preparation is generally described in New Trends and Developments  
5 in Vaccines, edited by Voller et al., University Park Press, Baltimore, Maryland, U.S.A. 1978. Conjugation of proteins to macromolecules is disclosed by Likhite, U.S. Patent 4,372,945 and by Armor et al., U.S. Patent 4,474,757.

### Description of drawings

10 FIG 1, Surface exposure of Cε3 and Cε4 of human IgE as calculated from the Padlan and Davis model 1986.

FIG 2, Histamine release inhibition and anaphylactogenicity of P14 antiserum. Monoclonal Antibodies, PTmAb0005 and PTmAb0011, which were used as positive controls, were added at 1 µg/ml to anti-BSA sera diluted 1/100 and 1/500 (final). The  
15 anti-P14 antisera were added at 1/100 and 1/500 final dilution. Cells were taken from an allergic patient sensitive to grass pollen, histamine release was triggered by incubation with this grass pollen allergen.

FIG 3, Histamine release inhibition and anaphylactogenicity of anti-P14 antiserum. The P14 antiserum from different mice, was added at different dilutions (80X or 40X)  
20 to contain approximately 1 µg/ml of anti-IgE antibody as measured by IgE receptor-bound ELISA. Three negative controls were used: Anti-BSA antiserum, non-specific IgG1 and a mixture of non-specific IgG1 diluted in anti-BSA antiserum. mAb11 is a monoclonal antibody known to inhibit histamine release and was used as a positive control (added at 2 µg/ml).

25 FIG 4, Histamine release inhibition and anaphylactogenicity of anti-P14 antiserum. Anti-P14 Antisera from different mice were added at a 1/50 final dilution. Monoclonal Abs were added at 2 µg/ml either in assay buffer or in anti-BSA sera dilution 1/50. Three negative controls were used: Anti-BSA antiserum, non-specific IgG1 and a mixture of non-specific IgG1 diluted in anti-BSA antiserum. mAb11 is a  
30 monoclonal antibody known to inhibit histamine release and was used as a positive control (added at 2 µg/ml).

FIG 5, Antibody response anti-P11. Peptide P11 is coated at 1 µg/ml in carbonate buffer at +4°C overnight. After saturation of plates, two-fold serial dilution of sera are added and incubated for 1h at 37°C. Bound IgG is detected with a biotinylated anti-mouse Ab followed by streptavidin-POD and TMB substrate. Time points measured

5 A. days 14 post vaccination 1, and day 14 post v2; B, Day 14 post v3.

FIG 6, Anti-P11 IgG anti-human IgE titres. Human IgE was coated at 1 µg/ml. Two-fold serial dilutions of sera ("BSA pool" is a pool of the control group) or PTmAb0005 (a positive control monoclonal antibody) were incubated for 1h at 37°C. Bound IgG is detected with a biotinylated anti-mouse Ab.

10 FIG 7, Histamine release inhibition studies with anti-P14 monoclonal antibodies, on allergic basophils donated by dustmite allergic patients (A10 and A11) and from grass pollen allergic patients (G8 and G4). PT11 (PTmAb0011) was used as a positive control, and non-specific IgG2a was used as an isotype control for the P14/23, P14/31 and P14/33.

15 FIG 8, IgE domain structure. (A) Each domain is composed of two facing β-sheets, shown in outline, one of 4 anti-parallel β-strands (labelled 4) and the other of 3 anti-parallel β-strands (labelled 3). (B) The seven strands are shown topographically as block arrows labelled a to f, partitioned between the two sheets as shown. The loop-connectivity of the strands is shown topologically with curved arrows: solid arrows are *intra*-sheet loops and dashed arrows are *inter*-sheet loops. In the IgG1 Fc domain structures a short c' strand forms part of the C-D loop, as is predicted for IgE Fc.

20 FIG 9, (A) Predicted structural alignment of the A-B loop sequences of human IgE domains Cε2, 3 & 4 with the equivalent segments from the crystallographically determined structure of human IgG1 Fc (domains Cγ2 & Cγ3). β-strands in the IgG1 structure are underlined and labelled a and b; amino acid residues at the ends of each sequence segment are numbered. Vertical arrows below the block of sequences point to predicted optimal cyclisation positions, labelled and connected by dashed or solid lines as shown in FIG 10b. (B) Predicted structural alignment of the c\_d loops of human IgE Cε2,3 & 4 with human IgG1 Fc. β-strands in the IgG1 structure are

25 underlined and labelled c, c' and d; amino acid residues at the ends of each sequence segment are numbered. Residues highlighted by the shaded boxes form (Cγ2 & Cγ3) or are predicted to form (Cε2, by homology model refinement and experiment, Cε3,

30

Cε4, by homology-modelling) a protected core within the loop. Residues within the plain bold boxes are predicted to be involved in recognition by receptors and/or antibodies. Vertical arrows below the block of sequences point to predicted optimal cyclisation positions, labelled and connected by dashed or solid lines as shown in FIG 11b.

FIG 10, (A) The schematic structure of the A-B hairpin at the sheet-sheet interface of Ig constant domains. Adjacent anti-parallel  $\beta$ -strands are shown as solid arrows, labelled *a* and *b*. Residues along strand *a* are labelled *i*, those along strand *b* are labelled *j*. Residues *i*+*n* & *j*+*m*, where both *n* and *m* are zero or even, form part of the sheet-sheet interface within a domain. Residues *i*+*n* & *j*+*m*, where both *n* and *m* are odd, form part of the solvent-exposed surface of a domain. The A-B loop is shown as a black arrow. (B) The schematic structure of the A-B hairpin as in figure 3a, with residue positions optimal for cyclisation connected by dashed or solid dumbbells.

FIG 11, (A) The schematic structure of the C-D hairpin (loop plus supporting  $\beta$ -strands) at the edge of the sheet-sheet interface of Ig constant domains. Opposing anti-parallel  $\beta$ -strands are shown as solid arrows, labelled *c* and *d*. Residues along strand *c* are labelled *i*, those along strand *d* are labelled *j*. Residues *i*+*n* & *j*+*m*, where *n* is odd but *m* is even, form part of the sheet-sheet interface within a domain. Residues *i*+*n* & *j*+*m*, where *n* is zero or even but *m* is odd, form part of the solvent-exposed surface of a domain. The c\_d loop, containing the short c' strand, is shown as a black arrow. (B) The schematic structure of the c\_d hairpin, with residue positions optimal for cyclisation connected by dashed or solid dumbbells.

The present invention is illustrated by but not limited to the following examples.

## **Part 1, Active vaccination studies**

### **Examples**

#### ***1.1 Peptide identification***

The peptides were identified by the following technique.

The modelled structure of human IgE has been described Padlan and Davies (*Mol. Immunol.*, 23, 1063-75, 1986). Peptides were identified which were both continuous and solvent exposed. This was achieved by using Molecular Simulations software (MSI) to calculate the accessibility for each IgE amino acid, the accessible surface was averaged over a sliding window of five residues, and thereby identifying regions of the IgE peptides which had an average over that 5-mer of greater than 80Å<sup>2</sup>.

The results of the test are shown in FIG 1.

## 10 Results

From figure 1 there are a number of native peptides which may be used as immunogens for raising antibodies against IgE.

15 **Table 4**, Native surface exposed and continuous IgE peptides using the 1986 Padlan and Davies model.

Peptide	Sequence	Location sequence and IgE Domain	SEQ ID NO.
P5	RASGKPVNHSTRKEEKQRNGTL	Cε3	1
P6	GTRDWIEGE	Cε3	2
P7	PHLPRALMRSTTKTSGPRA	Cε3/Cε4	3
P8	PEWPGSRDKRT	Cε4 (Pro451-Thr461)	4
P9	EQKDE	Cε4	5
P200	LSRPSPFDLFIRKSPTITC	Cε3	6
P210	WLHNEVQLPDARHSTTQPRKT	Cε4	7

In addition to those peptides identified above, the following peptides have been identified using the same selection criteria with the Helm *et al.* IgE model (2IgE model structure deposited 2/10/90 with PDB (Protein Data Bank, Research Collabarotory for Structural Bioinformatics; <http://pdb-browsers.ebi.ac.uk>)).

**Table 5**, Peptides identified using the Helm et al. 1990 model.

Name	Sequence	Location	SEQ ID NO.
1-90N	LFIRKS	Cε3	81
2-90N	PSKGTVN	Cε3	82
3-90N	LHNEVQLPDARHSTTQPRKTKGS	Cε4	83
4-90N	SVNPGK	Cε4	84

These peptides, or mimotopes thereof, were synthesised and conjugated to carrier proteins for use in immunogenicity studies.


5 **1.2 Synthesis of IgE peptide/Protein D conjugates using a succinimide-maleimide cross-linker**

Protein D may be conjugated directly to IgE peptides to form antigens of the present invention by using a maleimide-succinimide cross-linker. This chemistry allows controlled  $\text{NH}_2$  activation of carrier residues by fixing a succinimide group.


- 10 Maleimide groups is a cysteine-binding site. Therefore, for the purpose of the following examples, the IgE peptides to be conjugated require the addition of an N-terminal cysteine.

The coupling reagent is a selective heterobifunctional cross-linker, one end of the compound activating amino group of the protein carrier by an succinimidyl ester and the other end coupling sulhydryl group of the peptide by a maleimido group. The reactional scheme is as the following :

a. Activation of the protein by reaction between lysine and succinimidyl ester :



b. Coupling between activated protein and the peptide cysteine by reaction with the maleimido group :



### 1.3 Preparation of IgE peptide-Protein D conjugate

- 5 The protein D is dissolved in a phosphate buffer saline at a pH 7.2 at a concentration of 2.5 mg/ml. The coupling reagent (N-[γ-maleimidobutyryloxy] succinimide ester - GMBS) is dissolved at 102.5 mg/ml in DMSO and added to the protein solution. 1.025 mg of GMBS is used for 1 mg of Protein D. The reaction solution is incubated 1 hour at room temperature. The by-products are removed by a desalting step onto a
- 10 sephacryl 200HR permeation gel. The eluant used is a phosphate buffer saline Tween 80 0.1 % pH 6.8. The activated protein is collected and pooled. The peptides (as identified in tables 4 or 5, or derivatives or mimotopes thereof) is dissolved at 4 mg/ml in 0.1 M acetic acid to avoid di-sulfure bond formation. A molar ratio of between 2 to 20 peptides per 1 activated Protein D is used for the coupling. The
- 15 peptide solution is slowly added to the protein and the mixture is incubated 1 h at 25°C. The pH is kept at a value of 6.6 during the coupling phase. A quenching step is performed by addition of cysteine (0.1 mg cysteine per mg of activated PD dissolved at 4 mg/ml in acetic acid 0.1 M), 30 minutes at 25°C and a pH of 6.5. Two dialysis
- 20 against NaCl 150 mM Tween 80 0.1 % are performed to remove the excess of cysteine or peptide.

The last step is sterile filtration through a 0.22 μm membrane. The final product is a clear filtrable solution conserved at 4°C. The final ratio of peptide/PD may be determined by amino acid analysis.

In an analogous fashion the peptides of the present invention may be conjugated to other carriers including BSA. A pre-activated BSA may be purchased commercially from Pierce Inc.

- 5 Mimotopes of P8 (P14, SEQ ID NO. 20; CLEDGQVMDVDLL) and P5 (P11, SEQ ID NO. 8; CRASGKPVNHSTRKEEKQRNGLL) were synthesised which were conjugated to both Protein D and BSA using techniques described above.

#### 1.4 ELISA methods

##### 10 *Anti-peptide or Anti-peptide carrier ELISA*

The anti-peptide and anti-carrier immune responses were investigated using an ELISA technique outlined below. Microtiterplates (Nunc) are coated with the specific antigen in PBS (4° overnight) with either: Streptavidin at 2µg/ml (followed by incubation with biotinylated peptide (1µM) for 1 hour at 37°C), Wash 3X PBS-Tween 20 0.1%.

- 15 Saturate plates with PBS-BSA 1%-Tween 20 0.1% (Sat buffer) for 1 hr at 37°. Add 1° antibody = sera in two-step dilution (in Sat buffer), incubate 1 hr 30 minutes at 37°. Wash 3X. Add 2° anti-mouse Ig (or anti-mouse isotype specific monoclonal antibody) coupled to HRP. Incubate 1 hr at 37°. Wash 5X. Reveal with TMB (BioRad) for 10 minutes at room temperature in the dark. Block reaction with 0.4N H<sub>2</sub>SO<sub>4</sub>.

20

##### *Method for the Detection of Anti-Human IgE Reactivity in Mouse Serum (IgE plate bound ELISA)*

ELISA plates are coated with human chimaeric IgE at 1µg/ml in pH 9.6 carbonate/bicarbonate coating buffer for 1 hour at 37°C or overnight at 4°C. Non-specific binding sites are blocked with PBS/0.05% Tween-20 containing 5% w/v  
25 Marvel milk powder for 1 hour at 37°C. Serial dilutions of mouse serum in PBS/0.05% Tween-20/1% w/v BSA/4% New Born Calf serum are then added for 1 hour at 37°C. Polyclonal serum binding is detected with goat anti-mouse IgG-Biotin (1/2000) followed by Streptavidin-HRP (1/1000). Conjugated antibody is detected  
30 with TMB substrate at 450nm. A standard curve of PTmAb0011 is included on each plate so that the anti-IgE reactivity in serum samples can be calculated in µg/ml.

*Competition of IgE Binding with Mimotope Peptides, Soluble IgE or PTmAb0011*

Single dilutions of polyclonal mouse serum are mixed with single concentrations of either mimotope peptide or human IgE in a pre-blocked polypropylene 96-well plate. Mixtures are incubated for 1 hour at 37°C and then added to IgE-coated ELISA plates for 1 hour at 37°C. Polyclonal serum binding is detected with goat anti-mouse IgG-Biotin (1/2000) followed by Streptavidin-HRP (1/1000). Conjugated antibody is detected with TMB substrate at 450nm. For competition between serum and PTmAb0011 for IgE binding, mixtures of serum and PTmAb0011-biotin are added to IgE-coated ELISA plates. PTmAb0011 binding is detected with Streptavidin-HRP (1/1000).

*1.5 Human Basophil Assays*

Two types of assay were performed with human basophils (HBA), one to determine the anaphylactogenicity of the monoclonal antibodies, consisting of adding the antibodies to isolated PBMC; and a second to measure the inhibition of *Lol p I* (a strong allergen) triggered histamine release by pre-incubation of the HBA with the monoclonal antibodies.

Blood is collected by venepuncture from allergic donors into tubes containing heparin, and the non-erythrocytic cells were purified. The cells are washed once in HBH/HSA, counted, and re-suspended in HBH/HSA at a cell density of  $2.0 \times 10^6$  per ml. 100µl cell suspension are added to wells of a V-bottom 96-well plate containing 100µl diluted test sample or monoclonal antibody. Each test sample is tested at a range of dilutions with 6 wells for each dilution. Well contents are mixed briefly using a plate shaker, before incubation at 37°C for 30 minutes.

For each serum dilution 3 wells are triggered by addition of 10µl *Lol p I* extract (final dilution 1/10000) and 3 wells have 10µl HBH/HSA added for assessment of anaphylactogenicity. Well contents are again mixed briefly using a plate shaker, before incubation at 37°C for a further 30 minutes. Incubations are terminated by centrifugation at 500g for 5 min. Supernatants are removed for histamine assay using a commercially available histamine EIA measuring kit (Immunotech). Control wells



containing cells without test sample are routinely included to determine spontaneous and triggered release. Samples of cells were lysed by 2X freeze/thawing to assay total histamine contained in the cells.

- 5 The results are expressed as following:

*Anaphylactogenesis assay*

Histamine release due to test samples =

% histamine release from test sample treated cells – % spontaneous histamine release.

- 10 *Blocking assay*

The degree of inhibition of histamine release can be calculated using the formula:

% inhibition

$$= 1 - \frac{(\text{histamine release from test sample treated cells}^*)}{(\text{histamine release from antigen stimulated cells}^*)} \times 100$$

15

Values corrected for spontaneous release.

*Example 2, Immunisation of mice with P14 conjugates (P14-BSA, P14 -BSA) induces production of anti-human IgE antibodies.*

20

The conjugates comprising the mimotope P14 (25µg protein/dose), described in example 1, were administered into groups of 10 BalbC mice, adjuvanted with and oil in water emulsion containing QS21 and 3D-MPL described in WO 95/17210 .

Boosting was be performed on days 14, 24 and 72, sera was harvested 14 days after each immunisation.

25

The immune responses anti-peptide and anti-plate bound IgE was followed using ELISA methods described in Example 1. The antiserum was then tested for anaphylactogenicity and functional activity in the inhibition of histamine release from human allergic basophils (methods as described in example 1).

### *Immunogenicity Results*

Both conjugates, PD-P14 and BSA-P14, were capable of inducing anti-P14 and anti-IgE immune responses. The results for anti peptide and anti-IgE responses, induced by the BSA-P14 conjugates, as measured at day 14 post third and fourth vaccination, are shown in table 6. PTmAb0011 is a monoclonal antibody which is known to bind to the Cε2 domain of IgE, and was used to quantify the anti-IgE responses in µg/ml.

**Table 6, Immunogenicity results for BSA-P14 conjugates**

Anti-peptide responses (14 days post 3) Mid point titre			Anti-IgE responses (14 days post 3) (µg/ml (PTmAb0011))			Anti-IgE responses (14 days post 4) (µg/ml (PTmAb0011))		
AV	SD	GM	AV	SD	GM	AV	SD	GM
25974	22667	15492	9.9	2.18	0.7	22.9	33.5	4.8

*Table footnotes:* AV (average), SD (standard deviation), GM (geomean)

Mice vaccinated with BSA alone as controls did not generate any detectable anti-peptide or anti-IgE responses.

### *Functional activity results*

The antiserum raised by the P14 vaccination was found to be functional, in that it was potent in the inhibition of histamine release from allergic human basophils after triggering with allergen (see FIGS. 2, 3 and 4). Moreover, the antiserum was not found to be anaphylactogenic (FIGS. 2, 3 and 4).

### *Summary*

P14 (mimotope of P8) was shown to be capable of raising high titres of anti-P14 and anti-IgE antibodies in mice. These antibodies were subsequently shown to be functional, in that they inhibited histamine release from allergic human basophils, and were not anaphylactogenic. P14 and P8, therefore, may be used in the treatment or prophylaxis of allergy.

**Example 3, Immunisation of mice with P11 conjugates (P11-BSA, P11 -BSA) induces production of anti-human IgE antibodies.**

Human IgE epitope peptide P11 was coupled to maleimide-activated BSA (Pierce) (BSA-CRASGKPVNHSTRKEEKQRNGLL). 25 µg of conjugate formulated in SBAS2 was injected IM into 8 female BALB/c mice at days 0, 14 and 28. One control group of mice was injected with BSA/SBAS2. Blood samples were taken 14 days after each injection (a fourth bleeding was performed at day 24 post 3 to increase the availability of sera). Anti-peptide and anti-IgE antibodies raised by vaccination were measured by ELISA, as described in Example 1.

## 10 *Results*

A homogeneous IgG anti-P11 response could be detected already after one injection, but increased further after the second and third injection (FIG. 5a and 5b). All mice showed an anti-IgE response (ranging from 28 – 244 µg/ml as expressed in mAb005 equivalents) after a third injection (FIG. 6).

## Part 2, Functional activity of epitope specific monoclonal antibodies

### *Example 4, Functional activity of monoclonal antibodies raised against P14*

Monoclonal antibodies have been generated that recognise specifically P8 and mimotopes thereof, using techniques known in the art. Briefly, the P14-BSA conjugate described in part 1 of these examples, was injected into groups of Balb/C mice with the o/w adjuvant containing QS21 and 3D-MPL. Spleen cells were taken and fused with SP2/O B-cell tumour cell line, and supernatants were screened for reactivity against both P14 peptide and IgE. Several cell lines were generated, amongst which were P14/23, P14/31 and P14/33 which were deposited as Budapest Treaty patent deposit at ECACC on 26/1/00 under Accession No.s 00012610, 00012611, 00012612 respectively. All three monoclonal antibodies were confirmed to bind to IgE, and specifically to P14, by ELISA binding assays, and P14 competition assays against monoclonal antibody binding to IgE.

The functional activity of these monoclonal antibodies was assayed in the human basophil histamine release inhibition assay as described in Example 1.

### Results

5

All of the P14 monoclonal antibodies were tested on basophils taken from four different allergic patients (*A* patients were allergic to dust mite antigen, *G* patients were allergic to grass pollen). PT11 (PTmAb0011) was included as a positive control antibody which is known to inhibit histamine release *in vitro*. All of the three P14  
10 monoclonal antibodies (23, 31, and 33) were potent in inhibiting histamine release from allergic basophils (See FIG. 7).

**Example 5, Anti-IgE induced in mice after immunisation with conjugate are capable of blocking local allergic response in the Monkey Cutaneous Anaphylaxis model.**

15

P14/23 and P14/31 have also been tested for *in vivo* activity. Briefly, the local skin mast cells of African green monkeys were shaved and sensitised with intradermal administration of 100ng of anti-NP IgE (human IgE anti-nitrophenylacetyl (NP) purchased from Serotech) into both arms. After 24 hours, a dose range of the  
20 monoclonal antibodies to be tested were injected at the same injection site as the human IgE on one arm. Control sites on the opposite arm of the same animals received either phosphate buffered saline (PBS) or non-specific human IgE (specific for Human Cytomegalovirus (CMV) or Human Immunodeficiency Virus (HIV)). After 5 hours, 10 mg of a BSA-NP conjugate (purchase from Biosearch Laboratories)  
25 was administered by intravenous injection. After 15-30 minutes, the control animals develop a readily observable roughly circular oedema from the anaphylaxis, which is measurable in millimeters. Results are expressed in either the mean oedema diameter of groups of three monkeys or as a percentage inhibition in comparison to PBS controls. PTmAb0011, is a monoclonal antibody was used as a positive control.  
30 SBmAb0006 was used as a negative control.

Table 7, P14/23 results

Amount of sample to be tested ( $\mu$ g)	Mean diameter of oedema (mm)		
	P14/23	mAb0011	mAb0006
20	0	ND	12/15
10	0	0	17/19
1	15/13	0	20/20
0.1	15/12	ND	ND
0.05	15/15	ND	ND
0	15/15	ND	17/17

ND = Not done.

5 Table 8, P14/31 results

Amount of sample to be tested ( $\mu$ g)	Mean diameter of oedema (mm)		
	P14/31	mAb0011	mAb0006
20	0	ND	15/15
10	0	0	15/15
1	22/25	0	20/20
0.1	22/25	ND	ND
0.05	25/25	ND	ND
0	20/25	ND	20/25

As complete inhibition of anaphylaxis was observed with higher doses of monoclonal antibody, these antibodies are not anaphylactogenic *per se* when administered *in vivo*.

#### 10 Example 6, Structural aspects of IgE mimotopes

The present inventors have shown that the conformation in which the epitopes or mimotopes of the present invention is important for both anti-mimotope antibody recognition, and also for the ability of the peptides to generate a strong anti-IgE immune responses. As such the present inventors have developed structural rules  
 15 which predict the optimal sites for peptide cyclisation. Peptides that use these sites of cyclisation form one preferred aspect of the present invention.

As the full structure of IgE Fc has not been determined, the present inventors have refined the currently available models (Helm et al. *supra*, Padlan and Davis *supra*)

using the known structure of C $\gamma$ 2 and C $\gamma$ 3 of IgG1 (Deisenhofer J., 1981.Biochemistry, 20, 2361-2370). In addition, models of the C $\epsilon$ 2 domain have been built by comparison with known Ig folding-unit structures. The present inventors have designed these homology models of IgE Fc and thereby predicted the termini and the gross structure of intra-sheet (A-B loop, FIG 9A) and inter-sheet loops in IgE Fc domains (C-D loop, FIG 9B). Having defined the predicted IgE Fc A-B and C-D loops together with their supporting  $\beta$ -strands, mimotopes of the loops may be derived from the wild-type (WT) primary sequence of each loop by covalent cyclisation between chosen specific residues along the adjoining  $\beta$ -strands. Cyclisation is preferably realised by the formation of a disulphide bond between terminal cysteines which therefore combine to become a cystine.

Based upon our structural alignments (FIG 9A & 9B) we have derived simple predictive rules in order to enhance the probability that the conformations adopted by a mimotope, after conjugation to a suitable carrier molecule, are similar to those of the parent epitope.

#### Rule 1

The hydrophobic cystine group should replace WT  $\beta$ -strand residues that belong to the water-inaccessible core of the Ig constant domain, formed by the interface between the two  $\beta$ -sheets.

#### Rule 2i

For intra-sheet loops (e.g. the A-B loop) the cystine group should replace WT residues that are from adjacent anti-parallel  $\beta$ -strands (see FIG. 8) and that pack laterally together on the same side of the sheet. Following rule 1, this will be on the domain-interior side of the sheet. The structural derivation of this rule for the A-B loops is shown schematically in FIG 10 A and 10B.

#### Rule 2ii

For inter-sheet loops (e.g. the C-D loop) the cystine group should replace WT residues on anti-parallel  $\beta$ -strands, one strand from each sheet. Following rule 1, the

residues forming the optimal pair pack together from facing  $\beta$ -sheet surfaces, so forming part of the interface between the sheets. The structural derivation of this rule for the C-D loops is shown schematically in FIG. 11A and FIG. 11B. In the tables of putative mimotope sequences that follow, designs predicted to be optimal are underlined. Below each block of sequences the dotted and solid lines link the residue positions chosen for optimal cyclisation, which are also shown in the same way in FIG 10B (for A-B loops) and in FIG. 11B (for C-D loops).

Using the sequence alignment as shown in FIG 9A and 9B, together with the above rules, the present inventors have designed the following peptides listed in tables 9 to 12. The peptides which are underlined (in solid or dotted lines) are the optimal peptides according to the above identified rules, the same lines are shown in FIG 10B and FIG 11B. Non-underlined sequences are mimotopes.

15 *Table 9, IgE C $\epsilon$ 3 A-B loop sequences*

Peptide sequence (solid and dotted underlined are optimal)		SEQ ID NO.
341	357	
<u>C</u> <u>S</u> <u>R</u> <u>P</u> <u>S</u> <u>P</u> <u>F</u> <u>D</u> <u>L</u> <u>F</u> <u>I</u> <u>R</u> <u>K</u> <u>S</u> <u>P</u> <u>T</u> <u>I</u> <u>T</u> <u>C</u>		33
C S R P S P F D L F I R K S P T I C		34
<u>C</u> <u>S</u> <u>R</u> <u>P</u> <u>S</u> <u>P</u> <u>F</u> <u>D</u> <u>L</u> <u>F</u> <u>I</u> <u>R</u> <u>K</u> <u>S</u> <u>P</u> <u>T</u> <u>C</u>		35
C S R P S P F D L F I R K S P C		36
C R P S P F D L F I R K S P C		37
C R P S P F D L F I R K S P T C		38
C R P S P F D L F I R K S P T I C		39
C R P S P F D L F I R K S P T I T C		40
<u>C</u> <u>P</u> <u>S</u> <u>P</u> <u>F</u> <u>D</u> <u>L</u> <u>F</u> <u>I</u> <u>R</u> <u>K</u> <u>S</u> <u>P</u> <u>T</u> <u>I</u> <u>T</u> <u>C</u>		41
C P S P F D L F I R K S P T I C		42
<u>C</u> <u>P</u> <u>S</u> <u>P</u> <u>F</u> <u>D</u> <u>L</u> <u>F</u> <u>I</u> <u>R</u> <u>K</u> <u>S</u> <u>P</u> <u>T</u> <u>C</u>		43
C P S P F D L F I R K S P C		44

Table 10, IgE Cε4 A-B loop sequences

Peptide sequence (solid and dotted underlined are optimal)	SEQ ID NO.
<div style="display: flex; justify-content: space-between;"> <span>446</span> <span>463</span> </div> <u>C</u> <u>Y</u> <u>A</u> <u>F</u> <u>A</u> <u>T</u> <u>P</u> <u>E</u> <u>W</u> <u>P</u> <u>G</u> <u>S</u> <u>R</u> <u>D</u> <u>K</u> <u>R</u> <u>T</u> <u>L</u> <u>A</u> <u>C</u>	45
C Y A F A T P E W P G S R D K R T L C	46
<u>C</u> <u>Y</u> <u>A</u> <u>F</u> <u>A</u> <u>T</u> <u>P</u> <u>E</u> <u>W</u> <u>P</u> <u>G</u> <u>S</u> <u>R</u> <u>D</u> <u>K</u> <u>R</u> <u>T</u> <u>C</u>	47
C Y A F A T P E W P G S R D K R C	48
C A F A T P E W P G S R D K R C	49
C A F A T P E W P G S R D K R T C	50
C A F A T P E W P G S R D K R T L C	51
C A F A T P E W P G S R D K R T L A C	52
<u>C</u> <u>F</u> <u>A</u> <u>T</u> <u>P</u> <u>E</u> <u>W</u> <u>P</u> <u>G</u> <u>S</u> <u>R</u> <u>D</u> <u>K</u> <u>R</u> <u>T</u> <u>L</u> <u>A</u> <u>C</u>	53
C F A T P E W P G S R D K R T L C	54
C F A T P E W P G S R D K R T C	55
C F A T P E W P G S R D K R C	56



Table 11, IgE Cε3 C-D loop sequences

Peptide sequence (solid and dotted underlined are optimal)	SEQ ID NO.
373 387	
C T W S R A S G K P V N H S T R C	57
C T W S R A S G K P V N H S T C	58
C T W S R A S G K P V N H S C	59
C T W S R A S G K P V N H C	60
C W S R A S G K P V N H C	61
C W S R A S G K P V N H S C	62
C W S R A S G K P V N H S T C	63
C W S R A S G K P V N H S T R C	64
C S R A S G K P V N H S T R C	65
C S R A S G K P V N H S T C	66
C S R A S G K P V N H S C	67
C S R A S G K P V N H C	68

5

Table 12, IgE Cε4 C-D loop mimotope sequences

Peptide sequence (solid and dotted underlined are optimal)	SEQ ID NO.
477 491	
C Q W L H N E V Q L P D A R H S C	69
C Q W L H N E V Q L P D A R H C	70
C Q W L H N E V Q L P D A R C	71
C Q W L H N E V Q L P D A C	72
C W L H N E V Q L P D A C	73
C W L H N E V Q L P D A R C	74
C W L H N E V Q L P D A R H C	75
C W L H N E V Q L P D A R H S C	76
C L H N E V Q L P D A R H S C	77
C L H N E V Q L P D A R H C	78
C L H N E V Q L P D A R C	79
C L H N E V Q L P D A C	80

INDICATIONS RELATING TO DEPOSITED MICROORGANISM  
OR OTHER BIOLOGICAL MATERIAL

(PCT Rule 13bis)

<p>A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on page <u>18</u> line <u>7-13</u></p>	
<p>B. IDENTIFICATION OF DEPOSIT <span style="float: right;">Further deposits are identified on an additional sheet <input type="checkbox"/></span></p>	
<p>Name of depositary institution <b>European Collection of Cell Cultures</b></p>	
<p>Address of depositary institution (including postal code and country) <b>Vaccine Research and Production Laboratory Public Health Laboratory Service Centre for Applied Microbiology Research Porton Down, Salisbury Wiltshire SP4 0JG, GB</b></p>	
<p>Date of deposit <b>26 January 2000 (26/01/00)</b></p>	<p>Accession Number <b>00012610, 00012611 and 00012612</b></p>
<p>C. ADDITIONAL INDICATIONS (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span></p>	
<p>In respect of those designations where a European Patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European Patent or until the date on which the application has been refused or withdrawn, only by issue of such a sample to an expert nominated by the person requesting the sample.</p>	
<p>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)</p>	
<p>E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)</p>	
<p>The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")</p>	
<p>For receiving Office use only</p> <p><input type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer:</p>	<p>For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer:</p>

Form PCT/RO/134 (July 1998)

Claims

1. A peptide comprising an isolated surface exposed epitope of the Cε3 domain of IgE, wherein the peptide is P5 (SEQ ID No. 1), or mimotope thereof.
2. A peptide comprising an isolated surface exposed epitope of the Cε3 domain of IgE, wherein the peptide is P6 (SEQ ID No. 2), or mimotope thereof.
3. A peptide comprising an isolated surface exposed epitope of the region spanning Cε3 and Cε4 domains of IgE, wherein the peptide is P7 (SEQ ID No. 3), or mimotope thereof.
4. A peptide comprising an isolated surface exposed epitope of the Cε4 domain of IgE, wherein the peptide is P8 (SEQ ID No. 4), or mimotope thereof.
5. A peptide comprising an isolated surface exposed epitope of the Cε4 domain of IgE, wherein the peptide is P9 (SEQ ID No. 5), or mimotope thereof.
6. A peptide comprising an isolated surface exposed epitope of the Cε3 domain of IgE, wherein the peptide is P200 (SEQ ID No. 6), or mimotope thereof.
7. A peptide comprising an isolated surface exposed epitope of the Cε3 domain of IgE, wherein the peptide is P210 (SEQ ID No. 7), or mimotope thereof.
8. A peptide comprising an isolated surface exposed epitope of the Cε3 domain of IgE, wherein the peptide is 2-90N (SEQ ID No. 82), or mimotope thereof.
9. A peptide comprising an isolated surface exposed epitope of the Cε4 domain of IgE, wherein the peptide is 3-90N (SEQ ID No. 83), or mimotope thereof.
10. A peptide comprising an isolated surface exposed epitope of the Cε4 domain of IgE, wherein the peptide is 4-90N (SEQ ID No. 84), or mimotope thereof.
11. A mimotope as claimed in any one of claims 1 to 10 wherein the mimotope is a peptide.
12. A peptide as claimed in claim 4, wherein the mimotope of P8 is a peptide of the general formula:  

$$P, X_1, X_2, P, X_3, X_4, X_5, X_6, X_3, X_5$$
 wherein;  $X_1$  is an amino acid selected from E, D, N, or Q;  $X_2$  is an amino acid selected from W, Y, or F;  $X_3$  is an amino acid selected from G or A,  $X_4$  is an amino acid selected from S, T or M;  $X_5$  is an amino acid selected from R or K; and  $X_6$  is an amino acid selected from D or E.

13. A peptide as claimed in claim 12, wherein the mimotope of P8 is a peptide of the general formula P, X<sub>1</sub>, X<sub>2</sub>, P, G, X<sub>4</sub>, R, D, X<sub>5</sub>, X<sub>6</sub>,  
wherein; X<sub>1</sub> is an amino acid selected from E, D, N, or Q; X<sub>2</sub> is an amino acid selected from W, Y, or F; X<sub>4</sub> is an amino acid selected from S, T or M; X<sub>5</sub> is an amino acid  
5 selected from R or K; and X<sub>6</sub> is an amino acid selected from D or E.
14. An immunogen for the treatment of allergy comprising a peptide or mimotope as claimed in any one of claims 1 to 13, additionally comprising a carrier molecule.
15. An immunogen as claimed in claim 14, wherein the carrier molecule is selected from Protein D or Hepatitis B core antigen.
- 10 16. An immunogen as claimed in claim 14 or 15, wherein the immunogen is a chemical conjugate of the peptide or mimotope, or wherein the immunogen is expressed as a fusion protein.
17. An immunogen as claimed in any one of claims 14 to 16, wherein the peptide or peptide mimotope is presented within the primary sequence of the carrier.
- 15 18. A vaccine for the treatment of allergy comprising an immunogen as claimed in any one of claims 14 to 17, further comprising an adjuvant.
19. A ligand which is capable of recognising the peptides as claimed in any one of claims 1 to 13.
20. A ligand as claimed in claim 19, wherein the ligand is selected from P14/23, P14/31 or P14/33; which are deposited as Budapest Treaty patent deposit at ECACC  
20 on 26/1/00 under Accession No.s 00012610, 00012611, 00012612 respectively.
21. A pharmaceutical composition comprising a ligand as claimed in claim 19.
22. A pharmaceutical composition comprising a ligand as claimed in claim 20.
23. A peptide as claimed in any one of claims 1 to 13 for use in medicine.
- 25 24. A vaccine as claimed in claim 18 for use in medicine.
25. An immunogen as claimed in any one of claims 14 to 17, for use in medicine.
26. Use of a peptide as claimed in any one of claims 1 to 13 in the manufacture of a medicament for the treatment or prevention of allergy.
27. A ligand which is capable of recognising a peptide as claimed in any one of claims  
30 1 to 13, for use in medicine.
28. Use of a ligand which is capable of recognising a peptide as claimed in any one of claims 1 to 13, in the manufacture of a medicament for the treatment of allergy.

29. Use of P14/23, P14/31 or P14/33; which are deposited as Budapest Treaty patent deposit at ECACC on 26/1/00 under Accession No.s 00012610, 00012611, 00012612 respectively, in the identification of mimotopes of P8.

30. A peptide which is capable of being recognised by P14/23, P14/31 or P14/33;

5 which are deposited as Budapest Treaty patent deposit at ECACC on 26/1/00 under Accession No.s 00012610, 00012611, 00012612 respectively.

31. A vaccine comprising a peptide as claimed in claim 30.

32. A method of manufacturing a vaccine comprising the manufacture of an immunogen as claimed in any one of claims 14 to 17, and formulating the immunogen  
10 with an adjuvant.

33. A method for treating a patient suffering from or susceptible to allergy, comprising the administration of a peptide as claimed in any one of claims 1 to 13, to the patient.

34. A method for treating a patient suffering from or susceptible to allergy,

15 comprising the administration of a vaccine as claimed in claim 24 or 31 to the patient.

35. A method of treating a patient suffering from or susceptible to allergy comprising administration of a pharmaceutical composition as claimed in any one of claims 21 or 22, to the patient.

1/15

**Fig. 1**

IgE amino acid surface exposure.

Residue	Surface Area	average/5	> 50	> 80
PRO_108	70.754211	99.7733764	1	1
ARG_109	205.863144	89.6122724	1	1
GLY_110	48.697884	76.8830266	1	0
VAL_111	14.094634	65.4895302	1	0
SER_112	45.00526	46.920649	0	0
ALA_113	13.786729	41.2131878	0	0
TYR_114	113.018738	48.2957174	0	0
LEU_115	20.160578	69.0320708	1	0
SER_116	49.507282	68.9550828	1	0
ARG_117	148.687027	59.4319108	1	0
PRO_118	13.401789	66.4779462	1	0
SER_119	65.402878	65.1146108	1	0
PRO_120	55.390755	40.2327528	0	0
PHE_121	42.690605	41.3511228	0	0
ASP_122	24.277737	41.6901974	0	0
LEU_123	18.993639	62.3268566	1	0
PHE_124	67.098251	96.8962368	1	1
ILE_125	158.574051	111.7612278	1	1
ARG_126	215.537506	127.2638428	1	1
LYS_127	98.602692	115.6261678	1	1
SER_128	96.506714	90.3210972	1	1
PRO_129	8.909876	47.213596	0	0
Ce3 THR_130	32.048698	33.1289818	0	0
ILE_131	0	13.827639	0	0
THR_132	28.179621	23.4265788	0	0
CYS_133	0	17.1863608	0	0
LEU_134	56.904575	25.8134032	0	0
VAL_135	0.847608	29.5570474	0	0
VAL_136	43.135212	29.5570474	0	0
ASP_137	46.897842	21.0086596	0	0
LEU_138	0	41.1764274	0	0
ALA_139	14.162636	47.0972686	0	0
PRO_140	101.686447	52.0556626	1	0
SER_141	72.739418	55.9107072	1	0
LYS_142	71.689812	72.025412	1	0
GLY_143	19.275223	55.0721622	1	0
THR_144	94.73616	58.5342426	1	0
VAL_145	16.920198	49.6876606	0	0
ASN_146	90.04982	57.1762332	1	0
LEU_147	27.456902	39.7034882	0	0
THR_148	56.718086	39.9762418	0	0
TRP_149	7.372435	42.3791974	0	0
SER_150	18.283966	48.0311764	0	0
ARG_151	102.064598	61.6391216	1	0

SUBSTITUTE SHEET (RULE 26)

2/15

ALA_152	55.716797	68.7565726	1	0
SER_153	124.757812	98.5254416	1	1
GLY_154	42.95969	82.7176696	1	1
LYS_155	167.128311	92.7866728	1	1
PRO_156	23.025738	92.8627182	1	1
VAL_157	106.061813	100.8782402	1	1
ASN_158	125.138039	81.2024406	1	1
HIS_159	83.0373	83.8643042	1	1
SER_160	68.749313	100.1024634	1	1
THR_161	36.335056	101.6485648	1	1
ARG_162	187.252609	105.1675772	1	1
LYS_163	132.868546	113.1483374	1	1
GLU_164	100.632362	123.7075026	1	1
GLU_165	108.653114	117.1282088	1	1
LYS_166	89.130882	118.3834944	1	1
GLN_167	154.35614	123.8092514	1	1
ARG_168	139.144974	115.0634766	1	1
ASN_169	127.761147	101.3253922	1	1
GLY_170	64.92424	72.5768498	1	0
THR_171	20.44046	47.9994236	0	0
LEU_172	10.613428	23.3896668	0	0
THR_173	16.257843	15.9639244	0	0
VAL_174	4.712363	11.9144266	0	0
THR_175	27.795528	17.8898566	0	0
SER_176	0.192971	14.6768822	0	0
THR_177	40.490578	23.6673128	0	0
LEU_178	0.192971	19.1426268	0	0
PRO_179	49.664516	25.6114614	0	0
VAL_180	5.172098	23.0737176	0	0
GLY_181	32.537144	63.9982642	1	0
THR_182	27.801859	61.8714416	1	0
ARG_183	204.815704	65.9450374	1	0
ASP_184	39.030403	67.2307834	1	0
TRP_185	25.540077	90.5017958	1	1
ILE_186	38.965874	55.8821974	1	0
GLU_187	144.156921	60.762831	1	0
GLY_188	31.717712	68.4903946	1	0
GLU_189	63.433571	60.7744084	1	0
THR_190	64.177895	42.187322	0	0
TYR_191	0.385943	36.3067554	0	0
GLN_192	51.221489	49.1596714	0	0
CYS_193	2.314879	36.401281	0	0
ARG_194	127.698151	48.626639	0	0
VAL_195	0.385943	38.7900666	0	0
THR_196	61.512733	56.894756	1	0
HIS_197	2.038627	45.6995426	0	0
PRO_198	92.838326	51.6998584	1	0
HIS_199	71.722084	59.4304494	1	0

P6

SUBSTITUTE SHEET (RULE 26)

3/15

LEU_200	30.387522	101.1251104	1	1
PRO_201	100.165688	89.5911306	1	1
ARG_202	210.511932	89.3463034	1	1
ALA_203	35.168427	111.3965334	1	1
LEU_204	70.497948	119.0851456	1	1
MET_205	140.638672	94.506279	1	1
ARG_206	138.608749	90.6326938	1	1 P7
SER_207	87.617599	87.5937792	1	1
THR_208	15.800501	64.4796438	1	0
THR_209	55.303375	47.0393972	0	0
LYS_210	25.067995	51.8300146	1	0
THR_211	51.407516	57.0476686	1	0
SER_212	111.570686	69.0928378	1	0
GLY_213	41.888771	86.228067	1	1
PRO_214	115.529221	83.3757164	1	1
ARG_215	110.744141	72.0179718	1	0
ALA_216	37.145763	65.2725554	1	0
ALA_217	54.781963	48.4866956	0	0
PRO_218	8.161689	26.731915	0	0
GLU_219	31.599922	20.645257	0	0
VAL_220	1.970238	12.5988736	0	0
TYR_221	6.712473	13.1408914	0	0
ALA_222	14.550046	12.4753564	0	0
PHE_223	10.871778	14.6081692	0	0
ALA_224	28.272247	17.661842	0	0
THR_225	12.634302	46.3053972	0	0
PRO_226	21.980837	71.2281822	1	0
GLU_227	157.767822	65.7818486	1	0
TRP_228	135.485703	67.0606164	1	0
PRO_229	1.040579	84.6178212	1	1
GLY_230	19.028141	78.3797154	1	0 P8
SER_231	109.766861	74.5343982	1	0
ARG_232	126.577293	96.9868414	1	1
ASP_233	116.259117	99.3271062	1	1
LYS_234	113.302795	78.1251648	1	0
ARG_235	30.729465	52.8097062	1	0
THR_236	3.757154	30.0982028	0	0
LEU_237	0	7.4376438	0	0
ALA_238	2.7016	1.2917508	0	0
CYS_239	0	0.7718858	0	0
LEU_240	0	5.5314568	0	0
ILE_241	1.157829	19.4798026	0	0
GLN_242	23.797855	20.0640738	0	0
ASN_243	72.443329	29.58311	0	0
PHE_244	2.921356	31.2991972	0	0
MET_245	47.595181	45.895278	0	0
PRO_246	9.738265	41.159651	0	0
GLU_247	96.778259	45.6910524	0	0

SUBSTITUTE SHEET (RULE 26)



4/15

	ASP_248	48.765194	40.9067636	0	0
	ILE_249	25.578363	43.6417552	0	0
	SER_250	23.673737	44.292178	0	0
	VAL_251	23.413223	37.4696036	0	0
	GLN_252	100.030373	40.786536	0	0
	TRP_253	14.652322	39.9144442	0	0
	LEU_254	42.163025	55.3667468	1	0
Ca4	HIS_255	19.313278	64.0644808	1	0
	ASN_256	100.674736	87.8922836	1	1
	GLU_257	143.519043	94.9356644	1	1
	VAL_258	133.791336	125.7770554	1	1
	GLN_259	77.379929	117.4437004	1	1
	LEU_260	173.520233	100.4829132	1	1
	PRO_261	59.007961	88.7511612	1	1
	ASP_262	58.715107	97.0603256	1	1
	ALA_263	75.132576	64.316282	1	0
	ARG_264	118.925751	70.1529894	1	0
	HIS_265	9.800015	61.5777254	1	0
	SER_266	88.191498	59.9329928	1	0
	THR_267	15.838787	37.5523814	0	0
	THR_268	66.908913	51.6969256	1	0
	GLN_269	7.022694	65.771303	1	0
	PRO_270	80.522736	89.8671046	1	1
	ARG_271	158.563385	82.2153388	1	1
	LYS_272	136.317795	124.2368314	1	1
	THR_273	28.650084	122.369592	1	1
	LYS_274	217.130157	113.752525	1	1
	GLY_275	71.186539	89.1739554	1	1
	SER_276	115.47805	87.7550596	1	1
	GLY_277	13.424947	44.4062168	0	0
	PHE_278	21.555605	30.331391	0	0
	PHE_279	0.385943	7.235781	0	0
	VAL_280	0.81241	4.8371612	0	0
	PHE_281	0	3.2956898	0	0
	SER_282	1.431848	3.2185012	0	0
	ARG_283	13.848248	10.2740306	0	0
	LEU_284	0	10.6985678	0	0
	GLU_285	36.090057	16.7191372	0	0
	VAL_286	2.122686	37.9263888	0	0
	THR_287	31.534695	44.9612932	0	0
	ARG_288	119.884506	47.621104	0	0
	ALA_289	35.174522	48.1620878	0	0
	GLU_290	49.389111	53.3908726	1	0
	TRP_291	4.827605	46.7616094	0	0
	GLU_292	57.678619	74.1783896	1	0
	GLN_293	86.73819	74.2797528	1	0
	LYS_294	172.258423	95.33479	1	1
	ASP_295	49.895927	84.3393862	1	1

SUBSTITUTE SHEET (RULE 26)

5/15

GLU_296	110.102791	77.3154726	1	0
PHE_297	2.7016	42.863788	0	0
ILE_298	51.618622	50.8319354	1	0
CYS_299	0	28.8885658	0	0
ARG_300	89.736664	28.5866504	0	0
ALA_301	0.385943	19.2429276	0	0
VAL_302	1.192023	26.9888008	0	0
HIS_303	4.900008	9.4758236	0	0
GLU_304	38.729366	26.6422386	0	0
ALA_305	2.171778	35.9697824	0	0
ALA_306	86.218018	55.9203442	1	0
SER_307	47.829742	65.2374516	1	0
PRO_308	104.652817	74.870169	1	0
SER_309	85.314903	64.5256652	1	0
GLN_310	50.335365	61.2491192	1	0
THR_311	34.495499	57.5090542	1	0
VAL_312	31.447012	52.1974324	1	0
GLN_313	85.952492	53.3657582	1	0
ARG_314	58.756794	47.6630814	0	0
ALA_315	56.176994	54.8599582	1	0
VAL_316	5.982115	51.1280902	1	0
SER_317	67.431396	63.6157024	1	0
VAL_318	67.293152	62.0941464	1	0
ASN_319	121.194855	78.2977722	1	0
PRO_320	48.569214	119.372577	1	1
GLY_321	87.000244			
LYS_322	272.80542			

SUBSTITUTE SHEET (RULE 26)


6/15

**Fig. 2**


Histamine release inhibition and anaphylactogenicity of anti-P14 antiserum

% inhibition of Grass-allergen induced histamine release

1/100 1/500




Anaphylaxis (as % of allergen)



7/15

**Fig. 3**


Histamine release inhibition and anaphylactogenicity of anti-P14 antiserum.



8/15

**Fig. 4**

Histamine release inhibition and anaphylactogenicity of anti-P14 antiserum




9/15

**Fig. 5** Antibody response anti-P11.

A.

Figure 1a. IgG anti-P11, 14 post 1 and 2




Legend for Figure 1a:

- 1 14 p1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 1 14 p2
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 1 anti-BSA
- 2
- 3
- 4
- 5
- 6
- 7
- 8

B.


Figure 1b. IgG anti-P11, 14 post 3



Legend for Figure 1b:

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8





10/15

**Fig. 6** Anti-P11 IgG anti-human IgE titres.

11/15

**Fig. 7**

Histamine release inhibition activity of anti-P14 monoclonal antibodies.







12/15

**Fig. 8** IgE domain structure.



A. IgE Domain viewed face-on



B. IgE Domain viewed topologically

SUBSTITUTE SHEET (RULE 26)

13/15

**Fig. 9A** A-B loops**Fig. 9B** C-D loop

14/15

Fig. 10





Fig. 11



## SEQUENCE LISTING

5           <110> SmithKline Beecham Biologics s.a.  
            Peptide Therapeutics Ltd

            <120> Vaccine

10           <130> B45173

            <160> 86

            <170> FastSEQ for Windows Version 3.0

15           <210> 1  
            <211> 22  
            <212> PRT  
            <213> Human and artificial sequence

20           <400> 1  
Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys  
1                           5                           10                           15  
Gln Arg Asn Gly Thr Leu  
25                           20

            <210> 2  
            <211> 9  
            <212> PRT  
30           <213> Human and artificial sequence

            <400> 2  
Gly Thr Arg Asp Trp Ile Glu Gly Glu  
1                           5

35           <210> 3  
            <211> 19  
            <212> PRT  
            <213> Human and artificial sequence

40           <400> 3  
Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser Gly  
1                           5                           10                           15  
Pro Arg Ala

45           <210> 4  
            <211> 11  
            <212> PRT  
50           <213> Human and artificial sequence

            <400> 4  
Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr  
1                           5                           10

55           <210> 5  
            <211> 5  
            <212> PRT  
            <213> Human and artificial sequence

60           <400> 5  
Glu Gln Lys Asp Glu  
1                           5

65           <210> 6

<211> 19  
 <212> PRT  
 <213> Human and artificial sequence

5 <400> 6  
 Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr  
 1 5 10 15  
 Ile Thr Cys

10 <210> 7  
 <211> 21  
 <212> PRT  
 <213> Human and artificial sequence

15 <400> 7  
 Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr  
 1 5 10 15  
 Gln Pro Arg Lys Thr  
 20 20

<210> 8  
 <211> 23  
 <212> PRT  
 25 <213> Human and artificial sequence

<400> 8  
 Cys Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu  
 1 5 10 15  
 30 Lys Gln Arg Asn Gly Leu Leu  
 20 20

<210> 9  
 <211> 11  
 <212> PRT  
 35 <213> Human and artificial sequence

<400> 9  
 Gly Lys Pro Val Asn His Ser Thr Gly Gly Cys  
 1 5 10

<210> 10  
 <211> 18  
 <212> PRT  
 45 <213> Human and artificial sequence

<400> 10  
 Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys Gln Arg Asn  
 1 5 10 15  
 50 Gly Cys

<210> 11  
 <211> 20  
 <212> PRT  
 55 <213> Human and artificial sequence

<400> 11  
 Cys Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys Gln Arg  
 1 5 10 15  
 60 Asn Gly Leu Leu  
 20 20

<210> 12  
 <211> 14  
 <212> PRT

<213> Human and artificial sequence

<400> 12  
Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Gly Gly Cys  
5 1 5 10

<210> 13  
<211> 11  
<212> PRT  
10 <213> Human and artificial sequence

<400> 13  
Cys Gly Thr Arg Asp Trp Ile Glu Gly Leu Leu  
15 1 5 10

<210> 14  
<211> 12  
<212> PRT  
20 <213> Human and artificial sequence

<400> 14  
Cys Gly Thr Arg Asp Trp Ile Glu Gly Glu Thr Leu  
25 1 5 10

<210> 15  
<211> 12  
<212> PRT  
30 <213> Human and artificial sequence

<400> 15  
Gly Thr Arg Asp Trp Ile Glu Gly Glu Thr Gly Cys  
35 1 5 10

<210> 16  
<211> 12  
<212> PRT  
40 <213> Human and artificial sequence

<400> 16  
Cys His Pro His Leu Pro Arg Ala Leu Met Leu Leu  
45 1 5 10

<210> 17  
<211> 12  
<212> PRT  
50 <213> Human and artificial sequence

<400> 17  
Cys Gly Thr His Pro His Leu Pro Arg Ala Leu Met  
55 1 5 10

<210> 18  
<211> 13  
<212> PRT  
60 <213> Human and artificial sequence

<400> 18  
Thr His Pro His Leu Pro Arg Ala Leu Met Arg Ser Cys  
65 1 5 10

<210> 19  
<211> 14  
<212> PRT  
70 <213> Human and artificial sequence

<400> 19

Gly Pro His Leu Pro Arg Ala Leu Met Arg Ser Ser Ser Cys  
1 5 10

5 <210> 20  
<211> 13  
<212> PRT  
<213> Human and artificial sequence

<400> 20  
10 Ala Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Cys  
1 5 10

15 <210> 21  
<211> 17  
<212> PRT  
<213> Human and artificial sequence

<400> 21  
20 Ala Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Gly Gly  
1 5 10 15  
Cys

25 <210> 22  
<211> 17  
<212> PRT  
<213> Human and artificial sequence

<400> 22  
30 Cys Gly Gly Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr  
1 5 10 15  
Leu

35 <210> 23  
<211> 13  
<212> PRT  
<213> Human and artificial sequence

40 <400> 23  
Cys Thr Arg Lys Asp Arg Ser Gly Pro Trp Glu Pro Ala  
1 5 10

45 <210> 24  
<211> 15  
<212> PRT  
<213> Human and artificial sequence

<400> 24  
50 Ala Pro Cys Trp Pro Gly Ser Arg Asp Cys Arg Thr Leu Ala Gly  
1 5 10 15

55 <210> 25  
<211> 16  
<212> PRT  
<213> Human and artificial sequence

<400> 25  
60 Ala Cys Pro Glu Trp Pro Gly Ser Arg Asp Arg Cys Thr Leu Ala Gly  
1 5 10 15

65 <210> 26  
<211> 17  
<212> PRT  
<213> Human and artificial sequence



<400> 26  
Cys Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu Cys  
1 5 10 15  
Gly

<210> 27

<211> 16

<212> PRT

<213> Human and artificial sequence

<400> 27  
Cys Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Cys Gly  
1 5 10 15

<210> 28

<211> 13

<212> PRT

<213> Human and artificial sequence

<400> 28  
Thr Pro Cys Trp Pro Gly Ser Arg Asp Lys Arg Cys Gly  
1 5 10

<210> 29

<211> 11

<212> PRT

<213> Human and artificial sequence

<400> 29  
Cys Gly Ala Glu Trp Glu Gln Lys Asp Glu Leu  
1 5 10

<210> 30

<211> 11

<212> PRT

<213> Human and artificial sequence

<400> 30  
Ala Glu Trp Glu Gln Lys Asp Glu Phe Ile Cys  
1 5 10

<210> 31

<211> 9

<212> PRT

<213> Human and artificial sequence

<400> 31  
Gly Glu Gln Lys Asp Glu Phe Ile Cys  
1 5

<210> 32

<211> 10

<212> PRT

<213> Human and artificial sequence

<400> 32  
Cys Ala Glu Gly Glu Gln Lys Asp Glu Leu  
1 5 10

<210> 33

<211> 19

<212> PRT

<213> Human and artificial sequence

<400> 33

Cys Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr  
 1 5 10 15  
 Ile Thr Cys

5

<210> 34  
 <211> 18  
 <212> PRT  
 <213> Human and artificial sequence

10

<400> 34  
 Cys Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr  
 1 5 10 15  
 Ile Cys

15

<210> 35  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequence

20

<400> 35  
 Cys Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr  
 1 5 10 15  
 Cys

25

<210> 36  
 <211> 16  
 <212> PRT  
 <213> Human and artificial sequence

30

<400> 36  
 Cys Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Cys  
 1 5 10 15

35

<210> 37  
 <211> 15  
 <212> PRT  
 <213> Human and artificial sequence

40

<400> 37  
 Cys Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Cys  
 1 5 10 15

45

<210> 38  
 <211> 16  
 <212> PRT  
 <213> Human and artificial sequence

50

<400> 38  
 Cys Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Cys  
 1 5 10 15

55

<210> 39  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequence

60

<400> 39  
 Cys Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile  
 1 5 10 15  
 Cys

65

<210> 40

<211> 18  
 <212> PRT  
 <213> Human and artificial sequence

5       <400> 40  
 Cys Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile  
   1                  5                  10                  15  
 Thr Cys

10       <210> 41  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequence

15       <400> 41  
 Cys Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr  
   1                  5                  10                  15  
 Cys

20       <210> 42  
           <211> 16  
           <212> PRT  
           <213> Human and artificial sequence

25       <400> 42  
 Cys Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Cys  
   1                  5                  10                  15

30       <210> 43  
           <211> 15  
           <212> PRT  
           <213> Human and artificial sequence

35       <400> 43  
 Cys Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Cys  
   1                  5                  10                  15

40       <210> 44  
           <211> 14  
           <212> PRT  
           <213> Human and artificial sequence

45       <400> 44  
 Cys Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Cys  
   1                  5                  10

50       <210> 45  
           <211> 20  
           <212> PRT  
           <213> Human and artificial sequence

55       <400> 45  
 Cys Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg  
   1                  5                  10                  15  
 Thr Leu Ala Cys  
                   20

60       <210> 46  
           <211> 19  
           <212> PRT  
           <213> Human and artificial sequence

65       <400> 46  
 Cys Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg

1  
Thr Leu Cys

5

10

15

5  
<210> 47  
<211> 18  
<212> PRT  
<213> Human and artificial sequence

10  
<400> 47  
Cys Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg  
1 5 10 15  
Thr Cys

15  
<210> 48  
<211> 17  
<212> PRT  
<213> Human and artificial sequence

20  
<400> 48  
Cys Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg  
1 5 10 15  
Cys

25  
<210> 49  
<211> 16  
<212> PRT  
<213> Human and artificial sequence

30  
<400> 49  
Cys Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Cys  
1 5 10 15

35  
<210> 50  
<211> 17  
<212> PRT  
<213> Human and artificial sequence

40  
<400> 50  
Cys Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr  
1 5 10 15  
Cys

45  
<210> 51  
<211> 18  
<212> PRT  
<213> Human and artificial sequence

50  
<400> 51  
Cys Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr  
1 5 10 15  
55 Leu Cys

60  
<210> 52  
<211> 19  
<212> PRT  
<213> Human and artificial sequence

65  
<400> 52  
Cys Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr  
1 5 10 15  
Leu Ala Cys

5           <210> 53  
           <211> 18  
           <212> PRT  
           <213> Human and artificial sequence  
  
           <400> 53  
 10   Cys Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu  
       1                           5                           10                           15  
      Ala Cys  
  
 15           <210> 54  
           <211> 17  
           <212> PRT  
           <213> Human and artificial sequence  
  
           <400> 54  
 20   Cys Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu  
       1                           5                           10                           15  
      Cys  
  
 25           <210> 55  
           <211> 16  
           <212> PRT  
           <213> Human and artificial sequence  
  
           <400> 55  
 30   Cys Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Cys  
       1                           5                           10                           15  
  
 35           <210> 56  
           <211> 15  
           <212> PRT  
           <213> Human and artificial sequence  
  
           <400> 56  
 40   Cys Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Cys  
       1                           5                           10                           15  
  
           <210> 57  
           <211> 17  
 45   <212> PRT  
           <213> Human and artificial sequence  
  
           <400> 57  
 50   Cys Thr Trp Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg  
       1                           5                           10                           15  
      Cys  
  
 55           <210> 58  
           <211> 16  
           <212> PRT  
           <213> Human and artificial sequence  
  
           <400> 58  
 60   Cys Thr Trp Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Cys  
       1                           5                           10                           15  
  
 65           <210> 59  
           <211> 15  
           <212> PRT  
           <213> Human and artificial sequence

10

1 5 10

5 <210> 67  
 <211> 13  
 <212> PRT  
 <213> Human and artificial sequence

10 <400> 67  
 Cys Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser Cys  
 1 5 10

15 <210> 68  
 <211> 12  
 <212> PRT  
 <213> Human and artificial sequence

20 <400> 68  
 Cys Ser Arg Ala Ser Gly Lys Pro Val Asn His Cys  
 1 5 10

25 <210> 69  
 <211> 17  
 <212> PRT  
 <213> Human and artificial sequence

30 <400> 69  
 Cys Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His Ser  
 1 5 10 15  
 Cys

35 <210> 70  
 <211> 16  
 <212> PRT  
 <213> Human and artificial sequence

40 <400> 70  
 Cys Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His Cys  
 1 5 10 15

45 <210> 71  
 <211> 15  
 <212> PRT  
 <213> Human and artificial sequence

50 <400> 71  
 Cys Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg Cys  
 1 5 10 15

55 <210> 72  
 <211> 14  
 <212> PRT  
 <213> Human and artificial sequence

60 <400> 72  
 Cys Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Cys  
 1 5 10

65 <210> 73  
 <211> 13  
 <212> PRT  
 <213> Human and artificial sequence

<400> 73  
 Cys Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Cys  
 1 5 10

12



&lt;212&gt; PRT

&lt;213&gt; Human and artificial sequence

&lt;400&gt; 81

5 Leu Phe Ile Arg Lys Ser  
1 5

&lt;210&gt; 82

&lt;211&gt; 7

10 &lt;212&gt; PRT

&lt;213&gt; Human and artificial sequence

&lt;400&gt; 82

15 Pro Ser Lys Gly Thr Val Asn  
1 5

&lt;210&gt; 83

&lt;211&gt; 23

20 &lt;212&gt; PRT

&lt;213&gt; Human and artificial sequence

&lt;400&gt; 83

Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr Gln  
1 5 10 15  
25 Pro Arg Lys Thr Lys Gly Ser  
20

&lt;210&gt; 84

&lt;211&gt; 6

30 &lt;212&gt; PRT

&lt;213&gt; Human and artificial sequence

&lt;400&gt; 84

35 Ser Val Asn Pro Gly Lys  
1 5

&lt;210&gt; 85

&lt;211&gt; 13

40 &lt;212&gt; PRT

&lt;213&gt; Human and artificial sequence

&lt;400&gt; 85

45 Cys Pro Glu Trp Pro Gly Cys Arg Asp Lys Arg Thr Gly  
1 5 10

&lt;210&gt; 86

&lt;211&gt; 13

50 &lt;212&gt; PRT

&lt;213&gt; Human and artificial sequence

&lt;400&gt; 86

Thr Pro Glu Trp Pro Gly Cys Arg Asp Lys Arg Cys Gly  
1 5 10

## INTERNATIONAL SEARCH REPORT

national Application No

PCT/EP 00/01456

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K16/00 C07K16/42 A61K39/00 A61K39/385 A61K39/395  
G01N33/577 G01N33/68 A61P37/08

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

STRAND, CHEM ABS Data, MEDLINE, LIFESCIENCES, CANCERLIT, AIDSLINE, EMBASE, SCISEARCH, EPO-Internal, BIOSIS, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 98 24808 A (UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES, USA;PADLAN, EDUARDO) 11 June 1998 (1998-06-11)</p> <p>page 10 seq.ID 3 100% identity in 18aa overlap with seq.ID 6 page 3, line 10-24 page 4, line 21-23 page 11, line 16-29 page 28, line 32 -page 29, line 12 claims</p> <p style="text-align: center;">--- -/--</p>	<p>6, 14, 16-19, 21, 23-28, 32-35</p>

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

26 July 2000

Date of mailing of the international search report

02/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Covone, M

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/01456

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
O, X	STADLER, B.M. ET AL: "Mimotope and Anti-Idiotypic Vaccines to Induce an Anti-IgE Response" INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 'INT. ARCH. ALLERGY IMMUNOL.', (19990000) VOL. 118, NO. 2-4, PP. 119-121. ISSN: 1018-2438., September 1998 (1998-09), XP000929243 the whole document	1-14, 16-19, 21, 23-28, 32-35
X	PATENT ABSTRACTS OF JAPAN vol. 014, no. 543 (C-0783), 30 November 1990 (1990-11-30) -& JP 02 229200 A (DAINIPPON PHARMACEUT CO LTD; OTHERS: 01), 11 September 1990 (1990-09-11) abstract column 1 line 18 100% identity in 18aa overlap with seq. ID 7 and 100% identity in 18aa overlap with seq. ID 83	7, 9, 23, 26, 33
X	WO 93 04173 A (GENENTECH INC) 4 March 1993 (1993-03-04) page 57 table 6 seq. ID 14 100% identity in 10aa overlap with seq.ID1, seq.ID 16 100% identity in 9aa overlap with seq.ID 2	1, 2
A	WO 97 31948 A (CIBA GEIGY AG ;KRICEK FRANZ (AT); STADLER BEDA (CH)) 4 September 1997 (1997-09-04) page 4, line 6 -page 5, line 9 page 8, line 5-9 claims figure 4	1-35
A	LAFFER S ET AL: "Characterization of non-anaphylactogenic antihuman IgE antibody that completes with the IgE-high affinity Fce-receptor interaction." ALLERGY (COPENHAGEN), vol. 53, no. SUPPL. 43, 1998, pages 14-15, XP000929220 Annual Meeting of the European Academy of Allergology and Clinical Immunology; Birmingham, England, UK; June 21-26, 1998 ISSN: 0105-4538 the whole document	1-35

-/--

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 00/01456

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HEUSSER C ET AL: "Therapeutic potential of anti-IgE antibodies." CURRENT OPINION IN IMMUNOLOGY, (1997 DEC) 9 (6) 805-13. REF: 76 , 1997, XP002125679 page 805, right-hand column, paragraph 2 page 807, left-hand column, paragraphs 3,4 page 811, right-hand column, paragraph 3 -----	1-35
X,P	WO 99 67293 A (UNITED BIOMEDICAL INC., USA) 29 December 1999 (1999-12-29)  page 73 seq.ID 57 100% identity in 15aa overlap with sed.ID 1 page 72 seq.ID 49 seq.ID 57 100% identity in 9aa overlap with sed.ID 2, seq.ID 53 100% identity in 7aa overlap with sed.ID 82 page 21 seq.ID 5 100% identity in 13aa overlap with sed.ID 3 page 71 seq.ID 47 100% identity in 18aa overlap with sed.ID 6 page 8, line 4-17 page 41, line 10 -page 43, line 18 -----	1-3,6,8, 11,14, 16-19, 21, 23-28, 32-35

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim 29 (partially) is directed to a diagnostic method practised on the human/animal body, and claims 33-35 (completely) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/01456

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9824808 A	11-06-1998	AU 6532498 A	29-06-1998
JP 02229200 A	11-09-1990	NONE	
WO 9304173 A	04-03-1993	AU 2498192 A	16-03-1993
		AU 706584 B	17-06-1999
		AU 7038096 A	16-01-1997
		EP 0602126 A	22-06-1994
		JP 6509944 T	10-11-1994
		US 5965709 A	12-10-1999
		US 5994514 A	30-11-1999
WO 9731948 A	04-09-1997	AU 719609 B	11-05-2000
		AU 1879697 A	16-09-1997
		BR 9707819 A	27-07-1999
		CN 1213380 A	07-04-1999
		CZ 9802771 A	16-12-1998
		EP 0885244 A	23-12-1998
		HU 9901109 A	28-07-1999
		JP 2000502571 T	07-03-2000
		NO 983999 A	02-11-1998
		PL 328858 A	01-03-1999
		SK 118198 A	10-03-1999
WO 9967293 A	29-12-1999	AU 4580299 A	10-01-2000